An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Tumors or cancer of the human BREAST.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Pathological processes of the BREAST.
A cell line derived from cultured tumor cells.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Tumors or cancer of the LIVER.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The nursing of an infant at the breast.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
A malignant epithelial tumor with a glandular organization.
Radiographic examination of the breast.
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The conic organs which usually give outlet to milk from the mammary glands.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Surgical procedure to remove one or both breasts.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer of the LUNG.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
DNA present in neoplastic tissue.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the NASOPHARYNX.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Implants used to reconstruct and/or cosmetically enhance the female breast. They have an outer shell or envelope of silicone elastomer and are filled with either saline or silicone gel. The outer shell may be either smooth or textured.
An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
The inspection of one's breasts, usually for signs of disease, especially neoplastic disease.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Elements of limited time intervals, contributing to particular results or situations.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
MAMMARY GLANDS in the non-human MAMMALS.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Tumors or cancer of the COLON.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
Tumors or cancer of the ESOPHAGUS.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Tumors or cancer of the MOUTH.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
RNA present in neoplastic tissue.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Tumors or cancer of the SKIN.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.
Tumors or cancer of the STOMACH.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
Transplantation between animals of different species.
One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.
Tumors or cancer of the URINARY BLADDER.
Antibodies produced by a single clone of cells.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.
Tumors or cancer of the UTERINE CERVIX.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Surgical reconstruction of the breast including both augmentation and reduction.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Total mastectomy with axillary node dissection, but with preservation of the pectoral muscles.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
Large, branched, specialized sweat glands that empty into the upper portion of a HAIR FOLLICLE instead of directly onto the SKIN.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
A type II keratin that is found associated with the KERATIN-14 in the internal stratified EPITHELIUM. Mutations in the gene for keratin-5 are associated with EPIDERMOLYSIS BULLOSA SIMPLEX.
A fetal blood vessel connecting the pulmonary artery with the descending aorta.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
A type II keratin found associated with KERATIN-16 or KERATIN-17 in rapidly proliferating squamous epithelial tissue. Mutations in gene for keratin-6A and keratin-6B have been associated with PACHYONYCHIA CONGENITA, TYPE 1 and PACHYONYCHIA CONGENITA, TYPE 2 respectively.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
Tumors or cancer of the gallbladder.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis.
Tumors or cancer of the SALIVARY GLANDS.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

Characterization of human MMTV-like (HML) elements similar to a sequence that was highly expressed in a human breast cancer: further definition of the HML-6 group. (1/2323)

Previously, we found a retroviral sequence, HML-6.2BC1, to be expressed at high levels in a multifocal ductal breast cancer from a 41-year-old woman who also developed ovarian carcinoma. The sequence of a human genomic clone (HML-6.28) selected by high-stringency hybridization with HML-6.2BC1 is reported here. It was 99% identical to HML-6.2BC1 and gave the same restriction fragments as total DNA. HML-6.28 is a 4.7-kb provirus with a 5'LTR, truncated in RT. Data from two similar genomic clones and sequences found in GenBank are also reported. Overlaps between them gave a rather complete picture of the HML-6.2BC1-like human endogenous retroviral elements. Work with somatic cell hybrids and FISH localized HML-6.28 to chromosome 6, band p21, close to the MHC region. The causal role of HML-6.28 in breast cancer remains unclear. Nevertheless, the ca. 20 Myr old HML-6 sequences enabled the definition of common and unique features of type A, B, and D (ABD) retroviruses. In Gag, HML-6 has no intervening sequences between matrix and capsid proteins, unlike extant exogenous ABD viruses, possibly an ancestral feature. Alignment of the dUTPase showed it to be present in all ABD viruses, but gave a phylogenetic tree different from trees made from other ABD genes, indicating a distinct phylogeny of dUTPase. A conserved 24-mer sequence in the amino terminus of some ABD envelope genes suggested a conserved function.  (+info)

Spectral morphometric characterization of breast carcinoma cells. (2/2323)

The spectral morphometric characteristics of standard haematoxylin and eosin breast carcinoma specimens were evaluated by light microscopy combined with a spectral imaging system. Light intensity at each wavelength in the range of 450-800 nm was recorded for 10(4) pixels from each field and represented as transmitted light spectra. A library of six characteristic spectra served to scan the cells and reconstruct new images depicting the nuclear area occupied by each spectrum. Fifteen cases of infiltrating ductal carcinoma and six cases of lobular carcinoma were examined; nine of the infiltrating ductal carcinoma and three of the lobular carcinoma showed an in situ component. The spectral morphometric analysis revealed a correlation between specific patterns of spectra and different groups of breast carcinoma cells. The most consistent result was that lobular carcinoma cells of in situ and infiltrating components from all patients showed a similar spectral pattern, whereas ductal carcinoma cells displayed spectral variety. Comparison of the in situ and the infiltrating ductal solid, cribriform and comedo carcinoma cells from the same patient revealed a strong similarity of the spectral elements and their relative distribution in the nucleus. The spectrum designated as number 5 in the library incorporated more than 40% of the nuclear area in 74.08% of the infiltrating lobular cells and in 13.64% of the infiltrating ductal carcinoma cells (P < 0.001). Spectrum number 2 appeared in all infiltrating ductal cells examined and in none of the lobular cells. These results indicate that spectrum number 5 is related to infiltrating lobular carcinoma, whereas spectrum number 2 is characteristic for infiltrating ductal carcinoma cells. Spectral similarity mapping of central necrotic regions of comedo type in situ carcinoma revealed nuclear fragmentation into defined segments composed of highly condensed chromatin. We conclude that the spectral morphometric features found for lobular and ductal cell populations may serve future automated histological diagnostics.  (+info)

Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. (3/2323)

We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability. Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification. Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types. Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, we observed centrosome hyperamplification in tumors that retained wild-type p53. These tumors contained high levels of Mdm2. Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification. We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.  (+info)

Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. (4/2323)

CD40 is present on B cells, monocytes, dendritic cells, and endothelial cells, as well as a variety of neoplastic cell types, including carcinomas. CD40 stimulation by an antibody has previously been demonstrated to induce activation-induced cell death in aggressive histology human B-cell lymphoma cell lines. Therefore, we wanted to assess the effects of a recombinant soluble human CD40 ligand (srhCD40L) on human breast carcinoma cell lines. Human breast carcinoma cell lines were examined for CD40 expression by flow cytometry. CD40 expression could be detected on several human breast cancer cell lines and this could be augmented with interferon-gamma. The cell lines were then incubated with a srhCD40L to assess effects on in vitro growth. srhCD40L significantly inhibited the proliferation of the CD40(+) human breast cancer cell lines. This inhibition could also be augmented with interferon-gamma. Viability was also affected and this was shown to be due to increased apoptosis of the cell lines in response to the ligand. Treatment of tumor-bearing mice was then performed to assess the in vivo efficacy of the ligand. Treatment of tumor-bearing SCID mice with the ligand resulted in significant increases in survival. Thus, CD40 stimulation by its ligand directly inhibits human breast carcinoma cells in vitro and in vivo. These results suggest that srhCD40L may be of clinical use to inhibit human breast carcinoma growth.  (+info)

Induction of mammary carcinomas by N-methyl-N-nitrosourea in ovariectomized rats treated with epidermal growth factor. (5/2323)

The importance of epidermal growth factor (EGF) in both normal and malignant mammary gland development are presented in these studies. Initial findings demonstrated that in the absence of ovarian hormones, EGF had a significant proliferative effect on mammary epithelial cells. To determine whether mammary epithelial cells grown with EGF, in the absence of ovarian hormones, could be transformed by N-methyl-N-nitrosourea (MNU), female ovariectomized Lewis rats were implanted with pellets containing EGF for 1 week and then treated with MNU for initiation. Two days after MNU treatment, ovaries were implanted and EGF pellets were removed from all ovariectomized groups in order to promote carcinogenesis. The mammary carcinoma incidence of the EGF-stimulated group (90%) was not significantly different from the intact group (100%). The mammary cancer morphology of EGF-treated carcinomas was either ductal carcinoma or cribriform adenocarcinoma, whereas intact animals developed mainly papillary and occasional cribriform carcinomas. Fifty-eight percent of the carcinomas from the EGF group were ovarian hormone-independent compared with 10% of carcinomas from the intact group. These results demonstrate that EGF-induced proliferation during initiation with MNU was sufficient to induce the transformation of mammary carcinomas in the absence of ovarian hormones. The hormonal dependency of these EGF-induced carcinomas were different compared with MNU-initiated mammary carcinomas in intact rats.  (+info)

Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. (6/2323)

A centrosomal serine/threonine kinase, AIK1(3)/breast tumor amplified kinase/aurora2, which was recently identified as an oncogene, shows high amino acid identity with chromosome segregation kinases, fly Aurora, and yeast Ipl1. Immunohistochemical analyses of invasive ductal adenocarcinomas of the breast revealed that overexpression of AIK1 was observed in 94% of the cases, irrespective of the histopathological type, whereas the protein was not detected in normal ductal and lobular cells. Benign breast lesions including fibrocystic disease and fibroadenoma (epithelial components) displayed weakly detectable AIK1 expression in part of the lesions. This is the first immunohistochemical report of AIK1 expression in primary human breast carcinomas. Although the physiological function(s) of AIK1 kinase during cell division remains to be determined, the markedly high positivity of AIK1 staining in the cancer lesions suggested a possible involvement of its overexpression in the tumorigenesis of some of breast cancer cells.  (+info)

The influence of margin width on local control of ductal carcinoma in situ of the breast. (7/2323)

BACKGROUND: Ductal carcinoma in situ is a non-invasive carcinoma that is unlikely to recur if completely excised. Margin width, the distance between the boundary of the lesion and the edge of the excised specimen, may be an important determinant of local recurrence. METHODS: Margin widths, determined by direct measurement or ocular micrometry, and standardized evaluation of the tumor for nuclear grade, comedonecrosis, and size were performed on 469 specimens of ductal carcinoma in situ from patients who had been treated with breast-conserving surgery with or without postoperative radiation therapy, according to the choice of the patient or her physician. We analyzed the results in relation to margin width and whether the patient received postoperative radiation therapy. RESULTS: The mean (+/-SE) estimated probability of recurrence at eight years was 0.04+/-0.02 among 133 patients whose excised lesions had margin widths of 10 mm or more in every direction. Among these patients there was no benefit from postoperative radiation therapy. There was also no statistically significant benefit from postoperative radiation therapy among patients with margin widths of 1 to <10 mm. In contrast, there was a statistically significant benefit from radiation among patients in whom margin widths were less than 1 mm. CONCLUSIONS: Postoperative radiation therapy did not lower the recurrence rate among patients with ductal carcinoma in situ that was excised with margins of 10 mm or more. Patients in whom the margin width is less than 1 mm can benefit from postoperative radiation therapy.  (+info)

Prospective sonographic study of 3093 breast tumors. (8/2323)

To evaluate the predictive ability of sonographic tumor characteristics to differentiate benign from malignant tumors, we examined 3093 breast tumors (2360 benign and 733 malignant tumors) with ultrasonography. The ratio of the longest dimension to the anteroposterior diameter of benign tumors was significantly larger than that of malignant tumors (1.88+/-0.1 versus 1.69+/-0.02, P < 0.0001). Shape, margins, echogenicity, internal echo pattern, retrotumor acoustic shadowing, compressibility, and microcalcification were significant factors in the logistic regression model. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of breast sonography for malignancy were 86.1, 66.1, 44.1, 93.9, and 70.8%, respectively. Biopsy of the tumor for pathologic diagnosis is recommended if sonographic features are suggestive of malignancy.  (+info)

There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
Jin, R.,Bay, B.H.,Chow, V.T.K.,Tan, P.H.,Lin, V.C.L. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. British Journal of Cancer 83 (3) : 319-323. [email protected] Repository ...
Mas pin is a se rine p rotease inhibito r with tumo r-su p p resso r activity. Mas pin can su p p ress tumo r g rowth and metastasis in vivo and tumo r cell motility and invasion in vit ro. P revious
PURPOSE: Information on tubular carcinoma (TC) of breast is limited due to its rarity. A multi-institutional study was performed to investigate the prognosis and failure patterns of TC compared to invasive ductal carcinoma (IDC). MATERIALS AND METHODS: We collected retrospective data on 205 patients with TC from eleven institutions. For each TC case, 3 cases with IDC were matched according to similar size, t-stage, and n-stage from the same institution. Patterns of failure, disease free survival (DFS) and overall survival (OS) were assessed and compared between the groups. RESULTS: DFS at 5 years was 98.8% and 97.3% and OS at 5 years was 99.5% and 99.6% in TC and IDC, respectively. Among the patients with TC, 5 patients (2.4%) developed contralateral breast cancer, while 3 patients (0.5%) presented with contralateral breast cancer in patients with IDC. CONCLUSIONS: The TC of breast presents an excellent prognosis, but the contralateral breast cancer tends to be more frequently observed compared ...
We have lot of studies regarding Ductal Carcinoma in Situ (DCIS) succeeding into Invasive Ductal Carcinoma (IDC) of the breast. Still, there is hardly any study on the coexistence of both and its clinical significance.
Mai, K. T., Perkins, D. G. and Mirsky, D. (2003), Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma Examined with a Microscopic Three-Dimensional View. The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...
New research from Amsterdam shows that women over the age of 50 who have been diagnosed with ductal carcinoma in situ have a higher chance of being alive ten years after their diagnosis than women in the general population, according to Science Daily. Ductal carcinoma in situ is considered a disease separate from breast cancer because it is at stage 0 and does not spread around the body. However, ductal carcinoma in situ can progress into full-blown breast cancer, which is why it is still treated with surgery or surgery in combination with radiation therapy.. The researcher Dr. Lotte Elshof presented findings at the European Cancer Congress 2017. Women who have been diagnosed with ductal carcinoma in situ should feel better about their future because of these findings, which show their longevity will not be impacted by this condition.. Dr. Jelle Wesseling and her team at the Netherlands Cancer Institute followed approximately 10,000 Dutch women with ductal carcinoma in situ between the years ...
Invasive ductal carcinoma (IDC) is the most common form of breast cancer. Find out about IDC symptoms, diagnosis and treatment at Breast Cancer Care.
approximately three-quarters of breast cancers Invasive ductal carcinoma - 55% of breast cancers Ductal carcinoma in situ - 13% Invasive lobular carcinoma - 5% The overall 5-year survival rate for both ... Ductal carcinoma in situ, on the other hand, is in itself harmless, although if untreated approximately 60% of these low grade DCIS lesions will become invasive over the course of 40 years in follow-up ...
Invasive ductal carcinoma is the most commonly diagnosed breast cancer and has a tendency to metastasize via lymphatics. This lesion, which accounts for 75% of breast cancers, has no specific histolog... more
Background: Mounting evidence indicates that tumor-specific host immunity is associated with favorable prognosis in a variety of cancer settings. However, the role of immunity in breast cancer remains controversial. The purpose of this study was to determine the significance of tumor infiltrating leukocytes (TIL) with respect to pathological features and patient survival in estrogen receptor alpha (ER) negative breast cancer.. Patients and Methods: Tissue microarrays and immunohistochemistry were used to assess and categorize TIL in a cohort of 255 ER-negative invasive ductal breast carcinomas. Cases were registered by the Manitoba Breast Tumor Bank during the years 1988 to 2000 and had a minimum follow-up of 36 months. Stromal and intraepithelial TIL expressing the markers CD3, CD8, CD4, TIA1, CD25, FOXP3, CD20, CD68, and myeloperoxidase (MPO) were quantified by an experienced pathologist (PHW) and evaluated for associations with pathological parameters and survival. The median value for each ...
IDC. A reproduction print of my original watercolor painting depicting invasive ductal carcinoma, the most common type of breast cancer. Healthy duct cells are shown progressing into cancerous cells as you move around the painting. The cancerous cells spill out as they become invasive, but encounter chemotherapeutic drugs which attack the cells inducing apoptosis ...
Hello, I was recently diagnozed with Invasive Ductal Carcinoma. I am 26 years old and this was such a shock to me and my husband. There are really no support groups in my area and I would love to hear from anyone going through this. ------------------------------------------------------------------------ This is an automatically-generated notice. If youd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at ,,, or send an email message to: [email protected] with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where the phrase your-email-address is replaced with your actual email address ...
Purpose: The present study analyzed the polymorphisms of DNA repair genes and their impact on survival of patients with early breast cancer.Patients and methods: A total of 240 patients with surgically resected early invasive ductal breast cancer were enrolled in the present study, where patients who underwent neoadjuvant treatment were excluded. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen single nucleotide polymorphisms of 12 DNA repair genes were determined using the Sequenom Mass array system.Results: Among the target SNPs, VARS2 rs2074511 and POLE rs5744857 were found to correlate with relapse-free survival (RFS) after curative surgery in the log-rank test. There was no difference in the clinical and tumor characteristics according to the genotypes of these two coding variants except for the higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (p = 0.025). Multivariate analysis showed that the GG genotype of ...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive carcinoma of the breast. Current prognostic markers based on histopathological examination are unable to accurately predict which DCIS cases will progress to invasive carcinoma or recur after surgical excision. Epigenetic changes have been shown to be a significant driver of tumorigenesis, and DNA methylation of specific gene promoters provides predictive and prognostic markers in many types of cancer, including invasive breast cancer. In general, the spectrum of genes that are methylated in DCIS strongly resembles that seen in invasive ductal carcinoma. The identification of specific prognostic markers in DCIS remains elusive and awaits additional work investigating a large panel of methylatable genes by using sensitive and reproducible technologies. This review critically appraises the role of methylation in DCIS and its use as a biomarker ...
TY - JOUR. T1 - Treatment of low-risk ductal carcinoma in situ. T2 - is nothing better than something?. AU - Benson, John R.. AU - Jatoi, Ismail. AU - Toi, Masakazu. PY - 2016/10/1. Y1 - 2016/10/1. N2 - The heterogeneous nature of ductal carcinoma in situ has been emphasised by data for breast-cancer screening that show substantial increases in the detection of early-stage non-invasive breast cancer but no noteworthy change in the incidence of invasive and distant metastatic disease. Indolent non-progressive forms of ductal carcinoma in situ are managed according to similar surgical strategies as high-risk disease, with extent of resection dictated by radiological and pathological estimates of tumour dimensions. Although adjuvant treatments might be withheld for low-risk lesions, surgical treatments incur potential morbidity, especially when mastectomy and breast reconstruction are done for widespread low-grade or intermediate-grade ductal carcinoma in situ. Low rates of deaths from breast ...
Ivanka Dimova, Whole Genome Microarray Analysis In Invasive Ductal Breast Cancer Revealed The Most Significant Changes Affect Chromosomes 1, 8, 17 And 20, International Journal of Sciences 01(2015):8- ...
Invasive ductal carcinoma is the most common type of breast malignancy, with varying molecular features and resistance to treatment. Although CD44+/CD24- cells are believed to act as breast cancer stem cells and to be linked to poor prognosis in some patients, the association between these cells and tumor recurrence or metastasis in all or some types of invasive ductal carcinoma is unclear. A total of 147 randomly selected primary and secondary invasive ductal carcinoma samples were assayed for expression of CD44, CD24, ER, PR, and Her2. The association between the proportions of CD44+/CD24- tumor cells and the clinico-pathological features of these patients was evaluated. CD44+/CD24- tumor cells were detected in 70.1% of the tumors, with a median proportion of 5.8%. The proportion of CD44+/CD24- tumor cells was significantly associated with lymph node involvement (P = 0.026) and PR status (P = 0.038), and was correlated with strong PR status in patients with recurrent or metastatic tumors (P = 0.046)
Symptoms, diagnosis, treatment and prognosis for invasive ductal carcinoma-from the Johns Hopkins Breast Center in Baltimore, MD. Also get info for medullary, mucinous, papillary and tubular ductal carcinomas.
Recent studies suggest an association between chronic inflammation, modulating the tissue microenvironment, and tumor biology. Tumor environment consists of tumor, stromal and endothelial cells and infiltrating macrophages, T lymphocytes, and dendritic cells, producing an array of cytokines, chemokines and growth factors, accounting for a complex cell interaction and regulation of differentiation, activation, function and survival of tumor and surrounding cells, responsible for tumor progression and spreading or induction of antitumor immune responses and rejection. Tumor Necrosis Factor (TNF) family members (19 ligands and 29 receptors) represent a pleiotropic family of agents, related to a plethora of cellular events from proliferation and differentiation to apoptosis and tumor reduction. Among these members, BAFF and APRIL (CD257 and CD256 respectively) gained an increased interest, in view of their role in cell protection, differentiation and growth, in a number of lymphocyte, epithelial and
Hollie Quinn suffered from the typical health complaints of an adult female; these included heartburn and acid reflux, along with painful cysts, vertigo and migraines.. Hollie says that she ate the typically American diet which was low in vegetables, high in sugar, and drank soda daily. She never questioned the health directives given to her by her doctors, and was never told that there might be a connection between her health issues and the diet that she was eating.. In 2002, when Hollie was just 27 years old and in her 38th week of pregnancy, she was diagnosed with an infiltrating ductal carcinoma. This is the most common type of breast cancer which affects some 80% of patients, and as its name suggests, the cancer had broken through the milk duct and was invading the surrounding tissues of the breast. Over time, invasive ductal carcinomas can spread to the lymph nodes and to other areas of the body. Hollies main tumor was 2.3 cm, with a second tumor measuring 0.6 cm. The larger tumor was a ...
Invasive (infiltrating) ductal carcinoma of the breast is a malignant epithelial tumor resulted from proliferation of ductal epithelium of breast - Atlas of Pathology
Fig. 1. A, Western blot analyses of STK15 expression in breast carcinoma cell line BT474 and in a near diploid nontumorigenesis breast epithelial cell line MCF10 using the rabbit polyclonal anti-STK15 antibody. The specificity of the antibody is reflected in the detection of a single protein band in the top panel, and the absence of any detectable band in the middle panel in which the antibody was preabsorbed by the peptide antigen against which the antibody was raised. The presence of similar intensity β-actin bands in the lanes in the bottom panel indicates comparable amounts of protein loading from the cell lysates. B, immunohistochemical assay of STK15 expression in the cell lines, using paraffin-embedded sections of cells reflecting high expression in the breast carcinoma cell line BT474 and very low expression in MCF10 cells.. ...
In conclusion, Dr. Lori Pierce, Vice Provost for Academic and Faculty Affairs and Professor of Radiation Oncology at the University of Michigan, says this article has summarized nicely the major challenges facing breast cancer patients and their physicians in the management of ductal carcinoma in situ (DCIS). DCIS is not an invasive disease but can progress to invasive breast cancer, and potentially impact survival, in a significant number of women if not adequately treated when diagnosed. And we know that for those patients treated with lumpectomy, radiation to follow will reduce the chance of DCIS returning and/or invasive disease developing by at least 50%. We also know, however, that in some patients, the likelihood that DCIS will progress to invasive disease is very low even in the absence of treatment. Unfortunately, we have not found a reproducible way to predict those who need to be treated and those who dont but many researchers are working on this very question. For now, clinicians ...
This report presents data that show that women who are diagnosed with ductal carcinoma in situ (DCIS) are at significantly increased risk of being diagnosed with invasive breast cancer later on in...
(KudoZ) English to Spanish translation of Metastatic Ductal Carcinoma of the Breast: carcinoma ductal metastásico de mama [Medical (general) (Medical)].
The most common type of invasive breast cancer. It begins in the lining of the milk ducts (thin tubes that carry milk from the lobules of the breast to the nipple) and spreads outside the ducts to surrounding normal tissue.
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ.. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast. ...
To compare the lesion distribution and the extent of the disease in ductal and lobular carcinomas of the breast, we studied 586 ductal and 133 lobular consecutive cancers. All cases were documented on large-format histology slides. The invasive component of ductal carcinomas was unifocal in 63.3% (371/586), multifocal in 35.5% (208/586), and diffuse in 1.2% (7/586) of the cases. The corresponding figures in the lobular group were 27.8% (37/133), 45.9% (61/586), and 26.3% (35/133), respectively. When the distribution of the in situ and invasive component in the same tumors was combined to give an aggregate pattern, the ductal carcinomas were unifocal in 41.6% (244/586), multifocal in 31.6% (185/586), and diffuse in 26.8% (157/586) of the cases. The corresponding figures in the lobular category were 15.0% (20/133), 54.2% (72/133), and 30.8% (41/133), respectively. Ductal cancers were extensive in 45.7% (268/586), lobular in 65.4% (87/133) of the cases. All these differences were statistically ...
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.). ***Please note that cell lines are not for sale and unavailable for purchase.***. Fill out our tumor models contact form to get started setting up your next preclinical study with us.. Histotype: Mammary/Breast. Tumor Line: Human. REF# 3846. ...
The distribution of ductal carcinoma in situ DCIS grade in 4232 women and its impact on overdiagnosis in breast cancer screening. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
On July 23, 2008, I was diagnosed with bilateral breast cancer, invasive ductal carcinoma, Stage II, and ductal carcinoma in situ, Stage O. This blog was started to keep my family and friends connected during my surgery and treatment. This is my story!. ...
On July 23, 2008, I was diagnosed with bilateral breast cancer, invasive ductal carcinoma, Stage II, and ductal carcinoma in situ, Stage O. This blog was started to keep my family and friends connected during my surgery and treatment. This is my story!. ...
Mammography screening is deemed cost-effective for women aged 50-70. Yet the utilities informing breast screening policy are limited in their ability to adequately capture the benefits and risks. The evaluation of many cancer screening programmes present results in terms of cost per QALY but fail to include any disutility for the patients who have been over-diagnosed and may receive unnecessary treatment. This thesis presents an overview of the challenges associated with valuing breast cancer states, using the results of an empirical study deriving utilities from 172 women in Melbourne, Australia as an example of potential methods to capture the disutility of overtreatment. Ductal carcinoma in situ was used as a proxy to quantify the benefits and harms associated with the sequelae of screening. Utilities derived from 172 women for health states explicitly describing overdiagnosis were lower than those from the literature, where it is unlikely that women were informed that their treatment may ...
Queenie - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 7 years ago, Female, Age: 74, Stage I
copland16 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 9 years ago, Female, Age: 48, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
Rita - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 7 years ago, Female, Age: 50, Stage 0
penny364 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: about 5 years ago, Female, Age: 71, Stage 0, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
fortysomething - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 11 years ago, Female, Age: 50
djmandy - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Prefer not to answer/not applicable/unsure, Diagnosed: almost 10 years ago, Female, Age: 50, Stage 0
Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: almost 16 years ago, Female, Age: 53, Stage III, HER2 Positive: Yes, ER Positive: No, PR Positive: No
MarcieB - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 3 years ago, Female, Age: 73, Stage II, HER2 Positive: Yes, ER Positive: Yes, PR Positive: Yes
Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 9 years ago, Female, Age: 66, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
TY - JOUR. T1 - The immune microenvironment of breast ductal carcinoma in situ. AU - Thompson, Elizabeth. AU - Taube, Janis M.. AU - Elwood, Hillary. AU - Sharma, Rajni. AU - Meeker, Alan. AU - Warzecha, Hind Nassar. AU - Argani, Pedram. AU - Cimino-Mathews, Ashley. AU - Emens, Leisha A.. PY - 2016/3/1. Y1 - 2016/3/1. N2 - The host immune response has a key role in breast cancer progression and response to therapy. However, relative to primary invasive breast cancers, the immune milieu of breast ductal carcinoma in situ (DCIS) is less understood. Here, we profile tumor infiltrating lymphocytes and expression of the immune checkpoint ligand programmed death ligand 1 (PD-L1) in 27 cases of DCIS with known estrogen receptor (ER), progesterone receptor, and human epidermal growth factor 2 (HER-2) expression using tissue microarrays. Twenty-four cases were pure DCIS and three had associated invasive ductal carcinoma. Tumors were stained by immunohistochemistry for PD-L1, as well as the lymphocyte ...
Current clinicopathological parameters are useful predictors of breast ductal carcinoma in situ behaviour, but they are insufficient to define high risk patients for disease progression precisely. Thioredoxin interacting protein (TXNIP) is a key player of oxidative stress. This study aims to evaluate the role of TXNIP as a predictor of ductal carcinoma in situ progression. Tissue microarrays from 776 pure ductal carcinoma in situ and 239 mixed ductal carcinoma in situ and invasive tumors were constructed. All patients were treated at a single institution with a long-term follow-up and TXNIP expression was assessed using immunohistochemistry. TXNIP expression was investigated in terms of associations with clinicopathological and molecular features and patient outcome. Loss/reduced cytoplasmic expression of TXNIP was associated with features of aggressiveness including high nuclear grade (p=1.6x10-5), presence of comedo necrosis (p=0.001) and oestrogen receptor negative (ER-)/HER2- ductal ...
TY - JOUR. T1 - Sentinel lymph node identification in a primary ductal carcinoma arising in the vulva. AU - Martinez-Palones, J. M.. AU - Perez-Benavente, A.. AU - Diaz-Feijoo, B.. AU - Gil-Moreno, A.. AU - Roca, I.. AU - García-Jimenez, A.. AU - Aguilar-Martinez, I.. AU - Xercavins, J.. PY - 2007/3/1. Y1 - 2007/3/1. N2 - Primary or metastasic breast-like carcinoma of the vulva is a rare event. Because of the similarity with breast ductal carcinoma, we think that the same principles used for treatment of orthotopic breast cancer can be applied, as well as the use of sentinel lymph node technique, which is widely accepted in the management of early-stage breast cancer. We report a 49-old-year postmenopausal woman who was referred to our institution after small biopsy of a 3.5- × 3-cm right vulvar tumor. Histopathologically, infiltration of the vulvar dermis by a ductal carcinoma of mammary gland type was reported. At operation, the sentinel node technique revealed two sentinel nodes in the ...
Squamous cell carcinoma of the breast and its subtype, basal-human epidermal growth factor receptor 2 (HER2) phenotype, are very rare. Herein, we report a patient who developed recurrence of squamous cell carcinoma of the breast with basal-HER2 subtype 6 years after the initial diagnosis of invasive ductal carcinoma of the HER2 subtype. To the best of our knowledge, recurrence of invasive ductal carcinoma in the form of metaplastic squamous cell carcinoma of basal-HER2 subtype has not been reported previously. We present a pathological perspective of our experience ...
ConferenceSeries organizes Invasive Ductal Carcinoma national symposiums, conferences across the globe in association with popular Invasive Ductal Carcinoma associations and companies. OMICS group planned its conferences, and events in america, europe, middle east and asia pacific. locations which are popular with international conferences, symposiums and events are china, canada, dubai, uae, france, spain, india, australia, italy, germany, singapore, malaysia, brazil, south korea, san francisco, las vegas, san antonio, omaha, orlando, raleigh, santa clara, chicago, philadelphia, baltimore, united kingdom, valencia, dubai, beijing, hyderabad, bengaluru and mumbai
Gene expression profiling has taught us a great deal about the progression of fully-developed invasive breast cancer, and our study used this approach as a starting point to learn more about the progression of DCIS to invasive breast cancer. We are aware of at least 9 previous studies comparing expression between DCIS and invasive breast cancer, publishing results that can be compared with ours (8-16, 30). Collectively, these studies included 130 cases of DCIS and 126 of invasive breast cancer, which pales in comparison to previous expression profiling studies of invasive breast cancer alone involving thousands of cases. Our study increases the number of samples comparing DCIS to invasive breast cancer by about 50%, which is a helpful contribution given the relatively small numbers of cases overall addressing this important question.. A proportion of samples from this (17%) and the previous (37%) studies were paired DCIS and invasive breast cancer from the same breasts, which may not be the ...
AIMS--To determine if allelic loss on chromosomes 16q and 17p, commonly encountered in in situ and invasive ductal carcinomas, is present in atypical ductal hyperplasia (ADH); to determine whether ADH is a neoplastic (clonal) or hyperplastic (polyclonal) proliferation. METHODS--Fourteen cases of ADH were examined for allele loss at loci on chromosome 16q and 17p using a microdissection technique, polymorphic DNA markers and the polymerase chain reaction (PCR). RESULTS--Loss of heterozygosity (LOH) was detected in five of nine informative cases on chromosome 16q at the microsatellite D16S413 and two of eight informative cases on chromosome 17p at D17S796. CONCLUSIONS--The incidence of LOH at these loci is similar to that previously observed in ductal carcinoma in situ and in invasive ductal carcinoma. Because of the nature of the technique used, our findings also demonstrate that ADH is a monoclonal, and hence, neoplastic proliferation rather than a hyperplastic (polyclonal) condition as its name ...
Invasive lobular carcinoma (ILC), sometimes called infiltrating lobular carcinoma, is the second most common type of breast cancer after invasive ductal carcinoma. About 10% of all invasive breast cancers are invasive lobular carcinomas. Learn about the diagnosis and treatment of invasive lobular carcinoma.
Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Abstract: Background and Objectives: The initiating steps and precise pathway of breast tumorigenesis are poorly understood and it is unclear if Ductal Carcinoma In Situ (DCIS) progresses to invasive ductal carcinoma (IDCA) of the breast. This study was undertaken to identify proteins that are differentially expressed between IDCA and DCIS and that may predict the invasive potential of breast tumors. Methodology: It is utilized that the two-dimensional difference in gel electrophoresis technology (2D-DIGE) and tandem mass spectrometry (LC-MS/MS) to perform proteomic analysis of IDCA (MCF-7 and BT-474) and DCIS (HCC-1500 and HCC-38) cell lines. Results: Identified 10 proteins that were differentially expressed between IDCA and DCIS (≥2-fold difference; p≤0.05) and classified the proteins according to their Gene Ontology (GO). Out of these proteins, 60 kDa mitochondrial heat shock protein (HSPD1), Heat Shock Protein Beta 1 (HSPB1) and the voltage-dependent anion-selective channel protein 1 ...
Conducted in the three-county Seattle-Puget Sound metropolitan area, the population-based study included women ages 55 to 74 years: 880 of the women had invasive ductal breast cancer, 1,027 had invasive lobular breast cancer, and 856 of them had no cancer and served as the control group. Interviewing participants in person, researchers gathered in-depth histories of hypertension and heart disease, as well as risk factors for cancer, including family history, obesity, smoking, and alcohol use. Through a series of structured questions, the research also included detailed data regarding use of antihypertensive drugs, such as beginning and end dates of use, drug names, dose, route of administration, pattern of use, and indication ...
PHILADELPHIA - A recent report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, adds to the growing evidence that fish oil supplements may play a role in preventing chronic disease. Researchers at the Fred Hutchinson Cancer Research Center in Seattle, Wash., led by Emily White, Ph.D., a member of the public health sciences division, asked 35,016 postmenopausal women who did not have a history of breast cancer to complete a 24-page questionnaire about their use of non-vitamin, non-mineral specialty supplements in the Vitamins and Lifestyle (VITAL) cohort study. After six years of follow-up, 880 cases of breast cancer were identified using the Surveillance, Epidemiology and End Results registry. Regular use of fish oil supplements, which contain high levels of the omega-3 fatty acids, EPA and DHA, was linked with a 32 percent reduced risk of breast cancer. The reduction in risk appeared to be restricted to invasive ductal breast cancer, ...
The Y-box-binding protein 1 (YB-1), a member of the cold-shock domain RNA-and DNA-binding protein family, has pleiotropic functions such as regulation of the cell cycle. The aim of this study was to evaluate if YB-1 is a proliferative marker in breast cancer and elucidate potential downstream targets involved in YB-1-mediated cell cycle regulation using RNA interference technology. YB-1 protein expression was evaluated in tissue microarrays of 131 breast invasive ductal carcinomas by immunohistochemistry, while the YB-1 gene expression profile was evaluated in the T-47D, MDA-MB-231, ZR-75-1 and MCF7 breast cancer cell lines. Silencing of the YB-1 gene in T-47D breast cancer cells was performed using siRNA and the effects of down-regulation of YB-1 on cell growth and regulation of the cell cycle were ascertained. A focused panel of 84 genes involved in cell cycle progression was also examined. In tissue microarrays, YB-1 expression was shown to be associated with proliferating cell nuclear ...
Ductal carcinoma in situ is a noninvasive precancer condition. The treatment resembles the treatment of invasive breast cancer. The aim of this exploratory study was to gain knowledge on the level of postoperative pain, sensory disturbances, and distress among a small group of Danish women with ductal carcinoma in situ who had sentinel lymph node biopsy in order to plan a population study. A subgroup of patients with ductal carcinoma in situ (n = 20) was compared to patients with invasive breast cancer (n = 455) at time of diagnosis and after 12 months. Six patients were interviewed on the impact of the diagnosis and life after treatment. We found no significant difference in reported sensory disturbances or pain after 12 months between the groups. More than one-third (39%) of ductal carcinoma in situ patients reported moderate to severe distress (≥ 7 on the Distress Thermometer) at time of diagnosis decreasing to 10% after 12 months. Similarly 36% of breast cancer patients reported distress ...
BACKGROUND: To investigate markers for predicting breast cancer progression, we performed a candidate gene-based study that assessed expression change of three genes, cyclin D1, β-catenin, and metastasis-associated protein-1 (MTA1), involving in aggressive phenotypes of cancerous cells, namely hyperproliferation, epithelial-mesenchymal transition, and global transcriptional regulation.. METHODS: Specimens were from 150 enrolled female patients, with invasive ductal carcinoma, followed up for more than 10 years. mRNA expression of cyclin D1, β-catenin, and MTA1 in cancerous and noncancerous cells microdissected from the primary tumor site was determined by quantitative real-time PCR. The relationship between mRNA expression levels of the genes and clinicopathologic features was assessed by statistical analysis. Disease-free and overall survival (DFS and OS) were analyzed by Kaplan-Meier analysis with log-rank test and a multivariate Cox regression model.. RESULTS: Cyclin D1 was shown to be ...
Lobular breast cancer, or invasive lobular carcinoma, starts out in the lobules, the glands that produce milk. Learn about symptoms, treatments, and more.
Sirolimus in Preventing Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ, Lobular Carcinoma In Situ, Atypical Lobular Hyperplasia, or Atypical Ductal Hyperplasia - NCT02642094
Abstract Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast stroma by an intact layer of basement membrane and myoepithelial cells. DCIS is a non-obligate precursor of invasive breast cancer, and up to 40% of these lesions progress to invasive disease if untreated. Currently, it is not possible to predict accurately which DCIS would be more likely to progress to invasive breast cancer as neither the significant drivers of the invasive transition have been identified, nor has the clinical utility of tests predicting the likelihood of progression been demonstrated. Although molecular studies have shown that qualitatively, synchronous DCIS and invasive breast cancers are remarkably similar, there is burgeoning evidence to demonstrate that intra-tumor genetic heterogeneity is observed in a subset of DCIS, and that the process of progression to invasive disease may constitute an evolutionary bottleneck, resulting in the ...
Aimée was diagnosed with Stage 2B/3A Invasive Ductal Breast Cancer. She was selected as a pro-bono candidate for proton therapy and had a very successful run with it, totaling six weeks. She recently graduated on April 13, and received her medal of honor in the form of a challenge coin engraved with her patient number, 891. The coin signifies her fight against cancer, so she can put this chapter of her life behind her ...
TY - JOUR. T1 - Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. AU - Olsen, Lars Rønn. AU - Campos, Benito. AU - Winther, Ole. AU - Sgroi, Dennis C.. AU - Karger, Barry L.. AU - Brusic, Vladimir. PY - 2014/12/8. Y1 - 2014/12/8. N2 - Background: The majority of genetic biomarkers for human cancers are defined by statistical screening of high-throughput genomics data. While a large number of genetic biomarkers have been proposed for diagnostic and prognostic applications, only a small number have been applied in the clinic. Similarly, the use of proteomics methods for the discovery of cancer biomarkers is increasing. The emerging field of proteogenomics seeks to enrich the value of genomics and proteomics approaches by studying the intersection of genomics and proteomics data. This task is challenging due to the complex nature of transcriptional and translation regulatory mechanisms and the disparities between genomic and proteomic data from the same samples. In this ...
Aim of the study: Immunohistochemical evaluation of hormone receptors, Her2/neu, CK5/6, E-cadherin, beta-catenin, p53 and PTEN on Tissue Micro Array (TMA) of 46 Moroccan invasive breast carcinomas. Materials and Methods: The cases comprised 40 invasive ductal carcinomas, 4 invasive lobular carcinomas, 1 mixed carcinoma and 1 invasive colloid carcinoma. TMA paraffin blocs were prepared with the Beecher manual arrayer and immunostaining was performed using standard immunoperoxidase techniques. Results: 58.69% of the cases were ER positive. 43.18% (19/44) were triple negative breast cancers (TNBC) of which 15.78% (3/19) were of the basal phenotype expressing CK5/6. On the other hand, 72.22% (13/18) of the TNBC cases were IDC grade 3. Of the 18 IDC grade 3, 22.22% (4/18) were CK5/6 positive. 41.30% and 10.86% of the cases showed reduced expression of E-cadherin and beta-catenin respectively. Beta-catenin nuclear and cytoplasmic staining was noted in 20% and 97.82% respectively. p53 was overexpressed in 10
When a pathologist examines the tissue under a microscope, he or she looks for small clusters of tumor cells that appear to float in pools of mucin. The tumor may be made up mostly of mucin, or mostly of cancer cells separated by small amounts of mucin.. Mucinous carcinoma also can be found near, or mixed in with, other more common types of breast cancer. Sometimes a ductal carcinoma in situ (or DCIS, a cancer that has not spread outside the milk duct) is found near the mucinous carcinoma. A mucinous carcinoma also may have some areas within it that contain invasive ductal carcinoma cells. If the invasive ductal carcinoma cells make up more than 10% of the tumor, the cancer would be called a mixed mucinous carcinoma. A pure mucinous carcinoma means that at least 90-100% of the cells are mucinous.. Now or after surgery, the tissue should be tested for some other important features of a pure mucinous breast carcinoma:. ...
Our study found that a history of a clinical diagnosis of migraine is associated with a 26% reduced risk of breast cancer among both premenopausal and postmenopausal women. This result is consistent with the 33% reduction in risk of invasive ductal breast carcinomas observed in the only other published study to assess this relationship (1). In the data presented here, the association between migraine and breast cancer did not vary substantially by age at migraine diagnosis, but there was some suggestion that risks were lower among women who had used prescription migraine medications. Although we did not assess migraine severity, use of prescription medications may be a proxy for more severe disease, or this observation could also reflect a reduction in risk associated with use of these medications. The lack of a significant effect among women not using medication may also be the result of exposure misclassification because the proportion of women reporting a history of migraine who actually only ...
OS is a malignant tumor that occurs in bone tissues and mainly affects adolescents (16). Through developments in diagnostic and therapeutic techniques, the 5-year survival rate of patients with OS has increased by 60-70% in the last decade; however, the 20-year survival rate of patients with OS remains low, at ~20% (17,18). The mechanisms involved in the development of OS are largely unclear; thus, the identification of novel biomarkers in OS may be useful for future diagnosis and treatment of patients.. Dysregulated C-type lectins have been found in various diseases, including cancer (19,20). CLEC-2, a member of the C-type lectin family, was highly expressed in clear cell renal cell carcinoma and was positively associated with poor patient prognosis (21) and it was also observed to regulate cell proliferation and migration (22). CLEC3A, another C-type lectin, was reported to be highly expressed in breast invasive ductal carcinoma and promoted breast cancer cell proliferation and migration (8). ...
This is the first comprehensive study of MUC5AC immunoexpression in breast cancer. We detected MUC5AC expression in five of 68 cases, which included one pure colloid carcinoma (out of three cases) and four invasive ductal carcinomas (out of 65 cases). In a previous study, OConnell et al showed an altered pattern of mucin expression in mucinous (colloid) breast carcinomas.13 Using in situ hybridisation, these authors13 showed an increase of MUC2 and MUC5AC expression and a decrease of MUC1 expression in colloid breast carcinomas in comparison with non-colloid breast carcinomas. In the study of OConnell et al,13 MUC1 and MUC2 expression was studied by immunocytochemistry and in situ hybridisation, whereas the expression of MUC5AC was evaluated by in situ hybridisation alone. Our results reinforce their observations, showing that MUC5AC is overexpressed in some cases of colloid breast carcinoma. However, at variance with these authors13 we found that MUC5AC expression is not restricted to colloid ...
It is generally believed that atypical ductal hyperplasia (ADH) is a direct precursor of breast cancer and therefore portends breast cancer in the same breast, while atypical lobular hyperplasia (ALH) has an equal risk of cancer in both breasts and may not be a direct precursor of breast cancer. In the study, however, published in Cancer Prevention Research (2014;7;211-217) and led by Lynn C. Hartmann, MD, Professor of Oncology, cancer was twice as likely to occur in the breast having the biopsy, and this was true for both ADH and ALH.. Moreover, the findings run counter to current understanding that ALH primarily leads to lobular cancer. Instead, the researchers discovered that ALH was associated predominantly with later ductal cancers of the breast-also similar to cancers after ADH.. Both types resulted in invasive ductal cancers, and 69 percent were of intermediate or high grade. Further, about 25 percent had spread to the lymph nodes. Although the numbers were not statistically significant, ...
TY - JOUR. T1 - Should New No Ink On Tumor Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. AU - Merrill, Andrea L.. AU - Tang, Rong. AU - Plichta, Jennifer K.. AU - Rai, Upahvan. AU - Coopey, Suzanne B.. AU - McEvoy, Maureen P.. AU - Hughes, Kevin S.. AU - Specht, Michelle C.. AU - Gadd, Michele A.. AU - Smith, Barbara L.. PY - 2016/10/1. Y1 - 2016/10/1. N2 - Background: No consensus exists for clear margins for breast-conserving surgery for pure ductal carcinoma in situ (DCIS). We examined the implications of applying a no ink on tumor standard for pure DCIS by correlating clear margin width with rates of residual disease. Methods: Lumpectomies with complete shaved cavity margins (SCMs) for pure DCIS at our institution from 2004 to 2007 were reviewed and patients with microinvasive cancer or multifocal disease requiring multiple wires excluded. Rates of residual disease in shaved margins were determined based on ...
TY - JOUR. T1 - Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. AU - Shamliyan, Tatyana. AU - Wang, Shi Yi. AU - Virnig, Beth A.. AU - Tuttle, Todd M.. AU - Kane, Robert L.. N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.. PY - 2010/10. Y1 - 2010/10. N2 - We synthesized the evidence of the association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ of the breast. We identified five randomized controlled clinical trials and 64 observational studies that were published in English from January 1970 to January 2009. Younger women with clinically presented ductal carcinoma in situ had higher risk of ipsilateral recurrent cancer. African Americans had higher mortality and greater rates of advanced recurrent cancer. Women with larger tumor size, comedo necrosis, worse pathological grading, positive surgical margins, and at a higher risk category, using a ...
Invasive Lobular Carcinoma or ILC, is the second most common form of breast cancer after invasive ductal carcinoma. It is invasive meaning that it can spread or invade into the surrounding breast tissue. ILC is usually (but not always) positive for the oestrogen receptor and the progesterone receptor. This cancer is commonly found in women…
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
This multicentre retrospective study is characterised by a long period of accrual (median follow-up: 136 months,; range: 16-292 months), which offers the advantage of providing interesting information about the trend of the disease. A certain number of patients (12 patients) enrolled in the first years have died during this long period of observation; other patients (47 patients) didnt return for the planned examination to the Centre of Radiotherapy where they had been treated, and were lost to follow-up. In addition only approximately 20% of patients were treated in the first period (from 1985 to 1990) and the number of cases increased progressively during the following years (Figure 1). Most of the cases belong to the two decades covered by the screening activity. Nevertheless, a large number of cases were also found in the younger age group, between 41 and 50. Increased debate and publicity about breast cancer screening after the introduction of screening programmes could have determined an ...
Ductal carcinoma in situ (DCIS) is an early form of a non-invasive breast cancer that begins as abnormal cells inside the milk ducts in the breast. It typically doesnt show signs or symptoms and its estimated that up to 40% of cases eventually become invasive if not treated.. The current standard treatment is to perform a lumpectomy or a mastectomy in more extreme cases. Clinical trials are underway to determine if some patients with ductal carcinoma in situ might be able to avoid surgery. In addition to considering proton therapy to target the cancer, Mayo Clinic is conducting a clinical trial that involves a vaccine that could boost immunity against the HER2 receptor, says Dr. Amy Degnim, a surgeon with the Mayo Clinic Cancer Center. HER2 is a protein that in some cases is on the outside of cancer cells and for women with ductal carcinoma in situ, these receptors are present in about 50% to 60% of the cases. In this Mayo Clinic Q&A podcast Dr. Degnim, and one of her patients, Helen ...
Description of disease Breast, infiltrating lobular carcinoma of the. Treatment Breast, infiltrating lobular carcinoma of the. Symptoms and causes Breast, infiltrating lobular carcinoma of the Prophylaxis Breast, infiltrating lobular carcinoma of the
Clinical trial for Pleomorphic Lobular Breast Carcinoma In Situ | Lobular Breast Carcinoma in Situ | LCIS | Lobular Carcinoma In Situ | Atypical Hyperplasia of the Breast , Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
TY - JOUR. T1 - Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. AU - Yamaguchi, Mio. AU - Takagi, Kiyoshi. AU - Sato, Ai. AU - Miki, Yasuhiro. AU - Miyashita, Minoru. AU - Sasano, Hironobu. AU - Suzuki, Takashi. PY - 2020/9/1. Y1 - 2020/9/1. N2 - Background: RAS-related C3 botulinus toxin substrate 1 (Rac1) is a molecular switch fluctuating between GDP-bound inactive form (Rac1-GDP) and GTP-bound active form (Rac1-GTP) and involved in diverse function in both normal and malignant cells such as breast carcinoma cells. Although several studies have demonstrated immunolocalization of Rac1 protein in human breast carcinoma tissues, activation status of Rac1 still remains to be elucidated. Methods: We immunolocalized active form of Rac1 (Rac1-GTP) as well as total Rac1 using antibody specific for them in 115 invasive breast carcinoma tissues and correlated with clinicopathological parameters and clinical outcomes. Results: Rac1-GTP was ...
Hi. I did a search for Ductal Carcinoma and one of the hits was a letter from Jayna. I dont see anything else. Is there a web site I can go to? I would really like to find a lot more information about surgery, therapy and all alternatives. I know I am at the beginning of a long hard journey but I would like to give a little background which may help you point me in the right direction. I am 31 years old and back in August I found a lump. I spoke to my sister and a friend about it and both said wait a week or two to see if it would go away. I was a week away from my period so I waited. It did not go away. I called the OB/GYN and got an appointment for October 12th. I did not tell them about the lump, I guess I still figured it would go away. After I made the appointment I spoke to my mother, a breast cancer survivor twice. I told her the position of the lump and we both agreed that it was strange and would probably be nothing. Let me explain. My mother had breast cancer on the left side 11 years ...
Invasive lobular carcinoma has a much lower incidence than infiltrating ductal carcinoma, constituting less than 15% of cases of invasive breast cancer. It is characterized histologically by the &ldqu... more
Reducing cholesterol levels may inhibit breast cancer development, but the long-term use of cholesterol-lowering statin drugs is associated with more than double the risk of both types of breast cancer: invasive ductal carcinoma and invasive lobular carcinoma.
Background: Newer treatment modalities require subtyping of non-small cell lung carcinomas (NSCLC). Morphological differentiation is often difficult and various immunohistochemical (IHC) panels have been used to maximize the proportion of accurately subtyped NSCLC. Aim: The aim of this study was to subtype NSCLC on fine needle aspirates (FNA) using a minimal antibody panel. Materials and Methods: Cell blocks from 23 FNA samples with a morphological diagnosis of NSCLC were taken. IHC was evaluated (blinded to clinical data) for thyroid transcription factor-1 (TTF-1), cytokeratin (CK)7, CK20, and tumor protein p63. Results: TTF-1 was positive in 14 and negative in 9 cases. The p63 was positive in two cases each of TTF-1 positive and negative tumors. CK7 was positive in 12 of the 14 TTF-1 positive tumors and 4 of the TTF-1 negative tumors. CK20 was negative in all. All the 14 TTF-1 positive tumors were primary lung tumors, 12 being NSCLC and 2 being squamous cell carcinoma. Five of nine TTF-1 ...
The widespread adoption of screening mammography has led to an increase in the diagnosis of ductal carcinoma in situ (DCIS) of the breast. While it is estimated that 55,000 women in the US will be diagnosed with DCIS in 2013, only a small fraction of these women (~15%) will subsequently develop invasive breast cancer. However, most women with DCIS are treated as if they will develop invasive cancer. Almost a third of these women opt for a full mastectomy. In a majority of remaining women, the DCIS lesion is surgically excised with lumpectomy and, in over half of these women, additional radiation or tamoxifen treatment is provided. Thus, many women are receiving unnecessary adjuvant therapy to prevent invasive cancers that will not occur. Additionally, ~ 15% of women are not receiving adequate intervention because they will subsequently develop a subsequent invasive tumor even after receiving lumpectomy and adjuvant therapy. Identifying molecular markers that can accurately predict subsequent ...
TY - JOUR. T1 - A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. AU - Jakub, James W. AU - Murphy, Brittany L.. AU - Gonzalez, Alexandra B.. AU - Conners, Amy L.. AU - Henrichsen, Tara L.. AU - Maimone, Santo IV. AU - Keeney, Michael G.. AU - McLaughlin, Sarah A.. AU - Pockaj, Barbara A. AU - Chen, Beiyun. AU - Musonza, Tashinga. AU - Harmsen, William S.. AU - Boughey, Judy C. AU - Hieken, Tina J. AU - Habermann, Elizabeth B. AU - Shah, Harsh N.. AU - Degnim, Amy C. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time of excision. Patients with invasive disease are recommended to undergo axillary nodal staging, most often requiring a second operation. We developed and validated a nomogram to preoperatively predict percentage of risk for upstaging to invasive cancer. Methods: We reviewed 834 cases of DCIS ...
Objective: This study investigated whether gene expression levels of key modulators of the oxysterol signalling pathway modify the prognosis of patients with oestrogen receptor-positive (ER+) breast carcinomas via interaction with endocrine therapy. Context: The prognosis of patients with ER+ breast carcinoma depends on several factors. Previous studies have suggested that some oxygenated forms of cholesterol (oxysterols) bind to oestrogen receptor and anti-oestrogen binding site which may deregulate cholesterol homoeostasis and influence effect of therapy. Design: The expression levels of 70 oxysterol pathway genes were evaluated in a test set of breast carcinomas differing in ER expression. The genes differentially expressed in ER+ tumours were assessed in a comprehensive set of ER+ tumours to evaluate their clinical significance. Patients: A total of 193 primary patients with breast carcinoma were included. Measurements: The transcript levels were determined by quantitative real-time ...
Find the best invasive breast cancer doctors in Bangalore. Get guidance from medical experts to select invasive breast cancer specialist in Bangalore from trusted hospitals -
FRIDAY, Oct. 25, 2019 (HealthDay News) - For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the Annals of Surgical Oncology.. William H. Ward, M.D., from Naval Medical Center in Portsmouth, Virginia, and colleagues used the National Cancer Database to identify women with a clinical diagnosis of DCIS between 2004 and 2014. Differences in overall survival (OS) and presence of invasion were compared for five intervals between diagnosis and surgery (≤30, 31 to 60, 61 to 90, 91 to 120, and 121 to 365 days).. The researchers identified 140,615 clinical DCIS patients, of whom 123,947 had pathologic diagnosis of DCIS and 16,668 had invasive ductal carcinoma. Overall, five-year OS was 95.8 percent, and unadjusted median delay from diagnosis to surgery was 38 days. There was a 7.4 percent increased relative risk for death for each ...
At Moffitt Cancer Center, breast cancer research is one of our primary areas of focus. Not only are we looking to determine how ductal carcinoma in situ develops, but also how it can be treated more effectively. For instance, we are studying various hormonal therapies and how they affect hormone receptor-positive cancers, using our laboratory advances to improve outcomes and quality of life for each of our patients.. Our expert oncologists can further explain the causes of ductal carcinoma in situ. To make an appointment, call 1-888-663-3488 or submit a new patient registration form online. No referral is required.. Helpful Links:. ...
After having a lumpectomy, chemo and radiation my wife is 2 1/2 years out from treatment and has a recurrence. She is scheduled for a mastectomy. What type of follow up treatment is availible? Her 1...
Since the introduction of the National Health Service Breast Screening Programme (NHSBSP), the number of ductal carcinoma in situ (DCIS) cases has increased considerably. Despite its increased incidence, some NHS leaflets and reports do not mention it, and the general public seems largely unaware of its existence. There are numerous biological studies dealing with this condition, but its psychosocial aspects seem to have been neglected. We have only been able to locate two British studies (Farmer, A. 1996. Unpublished PhD thesis, University of Southampton; Webb, C. and Koch, T. 1997. J. Adv. Nurs., 25, 154-525) that address some of the psychosocial issues associated with DCIS. This paper starts by defining DCIS and explaining its usual presentation, natural history and epidemiology. The treatment options for DCIS are described, together with the great deal of confusion and lack of agreement that accompanies them. The psychological issues that women with screen-detected DCIS have to deal with are ...
The research goal of the Sukumar laboratory is to obtain a molecular profile of breast cancer and to apply this knowledge to the early detection, diagnosis and therapy of breast cancer. Toward this end, SAGE, array, and proteomic analysis of breast carcinomas is being performed on noninvasive (ductal carcinoma in situ), invasive (invasive ductal carcinoma), and metastatic breast cancer (bone, ovarian, brain metastasis). The goal is to obtain mRNA and protein profiles of each cell type composing the lesion. This will help derive gene expression signatures typical for each stage of breast cancer for epithelial, stromal, and endothelial cells. By such careful analysis, candidate genes are identified, characterized and utilized for early detection and/or therapy of breast cancer.. Previous gene searches in breast cancer performed here identified a number of potential candidate tumor suppressors and oncogenes. These belonged to families of genes involved in a variety of functions in the cell. ...
... removed from her left breast. The eventual diagnosis was "ductal carcinoma with medullary features".[failed verification] Due ... March 1, 1998 My Breast by Joyce Wadler on "Joyce Wadler on Her Own Breast Cancer Story -- New York Magazine - Nymag ... Her memoir about breast cancer, My Breast: One Woman's Cancer Story (ISBN 0671017756; ISBN 978-0-671-01775-0) was originally a ... Wadler has been treated for both breast and ovarian cancer. In 1991, Wadler was diagnosed with breast cancer and had a ...
... invasive ductal carcinoma, or other conditions. DCIS, or intraductal carcinoma, is by definition a breast cancer that is ... "Ductal Carcinoma In Situ (DCIS)". PubMed Health Glossary. DeSantis C, Siegel R, Bandi P, Jemal A (2011). "Breast cancer ... Clinical Breast Cancer. 6 (3): 216-22. doi:10.3816/cbc.2005.n.023. PMID 16137431. "Ductal carcinoma in situ". ... of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation ...
"Infiltrating Ductal Carcinoma of the Breast (Carcinoma of No Special Type)". Stanford University School of Medicine. Archived ... For example, there is routinely a quantification of mitotic count in breast cancer classification. The mitoses must be counted ...
"The influence of margin width on local control of ductal carcinoma in situ of the breast". The New England Journal of Medicine ... "A prognostic index for ductal carcinoma in situ of the breast". Cancer. John Wiley & Sons. 77 (11): 2267-2274. doi:10.1002/( ... Lewinsky is a board-certified radiation oncologist who is among the top 15% of breast cancer researchers in terms of ... Lewinsky has published a number of medical papers in collaboration with several other scientists that focus on breast cancer. ...
... lobular carcinoma in situ (LCIS) exhibits perinuclear staining with 34βE12. Ductal carcinoma in situ (DCIS) does not stain for ... Yeh IT, Mies C (March 2008). "Application of immunohistochemistry to breast lesions". Arch. Pathol. Lab. Med. 132 (3): 349-358 ... It can be used to differentiate in situ cancers of the breast; ...
"Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast". Breast Cancer Research and Treatment. 137 (3 ... Due to the concern over the relationship between HT and elevated breast cancer risk, breast cancer was selected as the primary ... Specifically, the reduction of breast cancer incidence persisted throughout the early post-intervention phase. Lower breast ... breast cancer followed by death directly attributed to the breast cancer) emerged (132 v 251 deaths; HR, 0.79; 95% CI, 0.64 to ...
Invasive Ductal Carcinoma (IDC) is one of the common types of breast cancer which accounts for 8 out of 10 of all invasive ... EVALUATION OF DUAL-SPECTRUM IR SPECTROGRAM SYSTEM ON INVASIVE DUCTAL CARCINOMA (IDC) BREAST CANCER. Institute of Biomedical ... Retrieved 29 April 2021.{{cite web}}: CS1 maint: url-status (link) "Invasive Ductal Carcinoma: Diagnosis, Treatment, and More ... While it is essential to detect breast cancer early to reduce the death rate there may be already more than 10,000,000 cells in ...
Kerlikowske, K, Tlsty T (2010-05-05). "Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In ... In 2015, she co-authored research into the use of 3D tissue culture models to study breast cancer cell generation and later ... This research had looked at wound cells in breast tissue, and identified 'repair cells' that could transform into a range of ... Heaven, Douglas (13 March 2013). "Are breast milk stem cells the real deal for medicine?". New Scientist. Retrieved 8 March ...
2011). "Role of RNA binding protein HuR in ductal carcinoma in situ of the breast". The Journal of Pathology. 224 (4): 529-539 ...
In 2009, Bell Calloway was diagnosed with ductal carcinoma, an early stage of breast cancer. She underwent two lumpectomies, ... She subsequently underwent reconstructive surgery, in which tissue from her stomach was used to reconstruct her breast. She ... Vanessa Bell Calloway Shares Her Breast Cancer Survival Story". Ebony. Retrieved November 1, 2018.{{cite web}}: CS1 maint: ...
Bone, cell nuclei (blue-purple), bone matrix (pink). Ductal carcinoma in situ (DCIS) in breast tissue, cell nuclei (blue-purple ... Basal cell carcinoma of the skin, cell nuclei (blue-purple), extracellular material (pink). Titford, M. (2005). "The long ...
"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland". Journal of ... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... "Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer ... In HER2 overexpressing breast cancers, the HER2-IL-6-STAT3 signaling relationship could be targeted to develop new therapeutic ...
"Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type". The Journal of ... C11orf86 is down-regulated from non-neoplastic mucosa to adenomas and carcinomas, down-regulated in renal cell carcinoma, and ... and carcinomas". Experimental and Molecular Pathology. 90 (2): 201-9. doi:10.1016/j.yexmp.2010.12.004. PMID 21185829. Hidaka H ... aberrant expression and functional significance in renal cell carcinoma". Oncotarget. 3 (1): 44-57. doi:10.18632/oncotarget.417 ...
In 2015, Steckloff was diagnosed with invasive ductal carcinoma, the most common form of breast cancer. Due to the diagnosis, ...
... gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast". Cancer Science. 100 (4): 580-7. doi:10.1111/j.1349- ...
"Infiltrating ductal carcinoma breast with central necrosis closely mimicking ductal carcinoma in situ (comedo type): a case ... May 1999). "Prognostic factors in ductal carcinoma in situ of the breast: results of a retrospective study of 575 cases. The ... ductal carcinoma. Recurrence and survival rates differ for invasive breast cancer which has originated as comedocarcinoma ... a diagnostic utility for differentiating breast carcinomas with ductal and lobular morphologies". Journal of Clinical and ...
... can be used to differentiate lobular carcinoma of the breast from ductal carcinoma of the breast. CAM 5.2, an antibody that ... such as spindle cell carcinoma. It is considered useful in identifying microscopic metastases of breast carcinoma in lymph ... October 2004). "Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients ... 1997). "A two-dimensional gel database of human colon carcinoma proteins". Electrophoresis. 18 (3-4): 605-13. doi:10.1002/elps. ...
"Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast". Am. J ... of clear cell renal carcinomas. Two transcript variants encoding different isoforms have been identified for this gene. Loss of ... "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau ...
Invasive ductal carcinomas of the breast often have a stellate appearance caused by desmoplastic formations. Desmoplasia ... Walker, Rosemary A (2001). "The complexities of breast cancer desmoplasia". Breast Cancer Research. 3 (3): 143-5. doi:10.1186/ ... malignant melanoma Desmoplastic squamous cell carcinoma Morpheaform basal cell carcinoma Microcystic adnexal carcinoma ... 2011). "Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs". Nature Medicine. 17 (7 ...
Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas]". ... FOXA1 in breast cancer is highly correlated with ERα+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 ... Song L, Xu Z, Zhang C, Qiao X, Huang C (August 2009). "Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell ... Expression of FOXA1 correlates with two EMT markers, namely Twist1 and E-cadherin in breast cancer. GRCh38: Ensembl release 89 ...
His mother died from ductal carcinoma a few months before the trip. The majority of his route included major highways (it's ... Hitchcock walked to raise funds for breast cancer research and aid to assist families dealing with the cost of hospital bills ...
... such as non-triple negative ductal carcinoma in situ, breast cancer, pancreatic adenocarcinoma, and colorectal carcinoma. It is ... Brown J (2016). Immunohistochemical and genomic analysis of ductal carcinoma in situ of the human breast (PDF) (Ph.D.). King's ... Nisha K (March 2017). Early Genomic Events Associated with Dissemination of Breast Cancer Cells (Ph.D.). University of Toronto ...
The lump grew in the following two weeks, and she was diagnosed with invasive ductal carcinoma in June 2019. While her father ... Her U.S. college career was interrupted by a breast cancer diagnosis in 2019. The only daughter of Terei Mangakahia, a Māori ... Shortly after being named to the Opals' preliminary Olympic squad, Mangakahia discovered a lump on her left breast while ... finds new purpose during breast cancer battle". Retrieved 21 February 2020. "Tiana Mangakahia's profile". archive. ...
State-of-the Science Conference on ductal carcinoma in situ; is a member of the early breast cancer clinical trialist group in ... McCaskill-Stevens co-directed the breast care and research center at the Indiana University Cancer Center. McCaskill-Stevens is ... the NCI Merit Award for breast cancer prevention; and listed on Ebony's 2013 Power 100 - Most Influential African Americans in ... and assumed responsibilities for breast cancer prevention with the community clinical oncology program (CCOP). She chaired the ...
"Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular ... elicits a humoral response in infiltrating ductal breast carcinomas: an immunoproteomics investigation". Clinical Biochemistry ... may lead to autoimmunity in breast cancer. As with breast cancer, upregulation of eEF1A expression is associated with prostate ... Shen R, Su ZZ, Olsson CA, Fisher PB (Jul 1995). "Identification of the human prostatic carcinoma oncogene PTI-1 by rapid ...
"Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular ... as has been observed for mRNA/protein levels of EEF1A1 in breast cancer.[non-primary source needed] Coding regions are composed ... "Immune-related microRNAs are abundant in breast milk exosomes". International Journal of Biological Sciences. 8 (1): 118-123. ...
"Allelotyping of Ductal Carcinoma in Situ of the Breast: Deletion of Loci on 8p, 13q, 16q, 17p and 17q". Cancer Research. 55 (15 ... and breast cancer. Donis-Keller, Helen; Maxam, Allan M.; Gilbert, Walter (1977). "Mapping adenines, guanines, and pyrimidines ... "The Cooperative Breast Cancer Tissue Resource: Archival Tissue for the Investigation of Tumor Markers". Clinical Cancer ...
"Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast". Mol. Carcinog ... 2006). "Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas". Mutat. Res. 594 (1-2): 78-85. doi ...
"Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma" (PDF). ... In a three dimensional model of breast ducts, reduced CSMD1 expression failed breast duct formation. Certain CSMD1 genetic ... It is a potential tumour suppressor, the deletion of which may result in head and neck carcinomas behaving more aggressively. ... CSMD1 protein expression was found to be reduced in patients with invasive breast cancer. Functional studies showed that CSMD1 ...
... -type ductal carcinoma in situ (DCIS) is not related to the skin conditions discussed here. DCIS is a noninvasive form of ... "Breast cancer treatment". Physician Desk Query. National Cancer Institute. Retrieved 13 June 2013. British Association of ... breast cancer, but comedo-type DCIS may be more aggressive, so may be more likely to become invasive. Oil production in the ...
Two small mtDNA insertions of ~260 and ~520 bp can be present in breast cancer, gastric cancer, hepatocellular carcinoma (HCC) ... show that ME2 genomic deletion in pancreatic ductal adenocarcinoma cells results in high endogenous reactive oxygen species, ... "Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases". Breast ... Breast[75][76][77][78]. X. X. X. X. 8470-13,447 and 8482-13459. X ...
... breast carcinomas (see ductal carcinoma in situ). The most common treatment for EPC tumors has been complete surgical resection ... Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the ... papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and ... invasive cribriform carcinoma of the breast, mucinous carcinoma, or tubular carcinoma tumors. Immunohistochemical analyses of ...
Zhou M (January 2018). "High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal ... "Hormone Therapy for Breast Cancer , Breast Cancer Treatment". Retrieved 2022-04-28. Hammerstrom AE, Cauley DH, ... "Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis". Cancer. 97 (8): 1894- ... "Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma". The American Journal of ...
"A clinicopthologic study of a rare clinical entity mimicking breast carcinoma: Idiopathic granulomatous mastitis". The Breast. ... maintaining tight junctions of the ductal epithelium, preventing involution of the breast gland after weaning and are known to ... Reddy KM, Meyer CE, Nakdjevani A, Shrotria S (2005). "Idiopathic Granulomatous Mastitis in the Male Breast". The Breast Journal ... "Cutaneous silicone granuloma mimicking breast cancer after ruptured breast implant". Case Reports in Dermatological Medicine. ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... spindle cell carcinoma and small-cell carcinoma. An invasive ductal carcinoma of the breast (pale area at the center) ... Radiation to the breast reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when ... for breast cancer, see Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. (February 2009). "Breast ...
Rao P, Shousha S (2010). "Male nipple adenoma with DCIS followed 9 years later by invasive carcinoma". The Breast Journal. 16 ( ... ductal carcinoma in situ (DCIS), syringomatous adenoma of the nipple and subareolar sclerosing duct hyperplasia. Lesions of the ... A nipple adenoma is a rare benign tumour of the breast. The condition may also be known as : Florid papillomatosis of the ... The microscopic appearance of a nipple adenoma can be mistaken for carcinoma. Other conditions that have similar symptoms and ...
... of invasive carcinomas. In the US, 55% of breast cancers are invasive ductal carcinoma. Invasive lobular carcinoma represent ... "Infiltrating Ductal Carcinoma of the Breast (Carcinoma of No Special Type)". Stanford University School of Medicine. Archived ... Ductal carcinoma in situ: 99% - Kerlikowske, K (2010). "Epidemiology of ductal carcinoma in situ". Journal of the National ... either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Stages 1-3 are within the breast or regional lymph ...
Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, Lu YF, Yu LH, Li JP, Li ZS (2013). "Expression of NEDD9 in pancreatic ductal ... NEDD9 depletion sensitizes breast tumor cell lines to the Aurora A inhibitor alisertib. Consideration of NEDD9 as a biomarker ... and renal cell carcinoma cells. A non-coding RNA, named B2, extending from 10 kb upstream of NEDD9 exon 1 to exon 4 has been ... Inhibition of AURKA and HDAC6 activity by alisertib and tubastatin A in xenograft models of breast cancer has led to a decrease ...
It is believed that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade mammary ductal carcinoma, whereas ... Atypical hyperplasia is a high-risk premalignant lesion of the breast. ...
... for prostate cancer found that NSAAs induced full ductal development and moderate lobuloalveolar development of the breasts ... Kennealey GT, Furr BJ (February 1991). "Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma". Urol. ... of breast volume (with the bulk of the breasts (80-90%) being represented by stromal or adipose tissue), and it is uncertain to ... In transgender women, breast development is a desired effect of antiandrogen and/or estrogen treatment. Bicalutamide induces ...
The cells technically came from a triple-negative breast cancer, which was caused by an invasive ductal carcinoma in the ... Lasfargues, EY; Ozzello, L (1958). "Cultivation of human breast carcinomas". Journal of the National Cancer Institute. 21 (6): ... BT-20 is a breast cancer cell line derived from a 74-year-old human female in 1958 by E.Y. Lasfargues and L. Ozzello. ... The cells express an estrogen receptor with a deletion of exon 5, and are used in preclinical studies of breast cancer. ...
"Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ ... Whether LVI is a significant prognostic factor in breast cancer is widely debated, and there is no clear consensus. In ... In sporadic colorectal carcinoma, LVI of a poorer prognosis. Perineural invasion Malignancy Han JS, Molberg KH, Sarode V (2011 ... Moreira LF, Kenmotsu M, Gochi A, Tanaka N, Orita K (1999). "Lymphovascular and neural invasion in low-lying rectal carcinoma". ...
Lu RQ, Sun M, Gao X, Guo L (March 2012). "[Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological ... For instance, in human breast cancer (MCF7) cells, PNKD may promote tumor cell proliferation by activating the MEK/ERK ... Overexpression of PNKD has also been associated with multiple cancers, including pancreatic ductal adenocarcinoma, gastric ... "Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal ...
Sykes announced that she had been diagnosed earlier in the year with ductal carcinoma in situ (DCIS). Although DCIS is a non- ... invasive "stage zero breast cancer", Sykes had elected to have a bilateral mastectomy in order to lower her chances of getting ... breast cancer. Sykes splits time between Media, Pennsylvania, a suburb of Philadelphia, and Cherry Grove, New York. Sykes ...
Bile acids have been found to stimulate carcinogenesis in pancreatic ductal adenocarcinoma cells through increased expression ... elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast ... in papillary thyroid carcinoma". Thyroid. 21 (7): 745-50. doi:10.1089/thy.2010.0339. PMID 21615302. Doyle LA, Möller E, Dal Cin ... Bile accelerates carcinogenic processes in pancreatic ductal adenocarcinoma cells through the overexpression of MUC4. Sci Rep. ...
SLC22A1L Breast cancer; 114480; TP53 Breast cancer, early-onset; 114480; BRIP1 Breast cancer, invasive ductal; 114480; RAD54L ... FLCN Renal cell carcinoma; 144700; DIRC2 Renal cell carcinoma; 144700; HNF1A Renal cell carcinoma; 144700; RNF139 Renal cell ... Breast cancer, somatic; 114480; AKT1 Breast cancer, somatic; 114480; KRAS Breast cancer, somatic; 114480; PIK3CA Breast cancer ... OGG1 Renal cell carcinoma, papillary, 1; 605074; PRCC Renal cell carcinoma, papillary, 1; 605074; TFE3 Renal cell carcinoma, ...
Dust ectasia, with nipple retraction Mastitis in breast Diagram showing ductal carcinoma in situ (DCIS) Paget's disease of the ... Nipple discharge is the third most common breast complaint by women, after breast pain and a breast lump. About 3% of breast ... Nipple discharge is the third most common breast complaint by women, after breast pain and a breast lump. 10% of women can ... Ductal carcinoma in situ (DCIS) usually presents with abnormal findings on mammography, but can less frequently present with a ...
Patients with invasive carcinomas have shown ID4 expression in their breast cancer specimens. This has been identified as a ... suppressor factory in human breast tissue where oestrogen is responsible for regulation of ID4 expression in the mammary ductal ... ID4 is constitutively expressed in normal human mammary epithelium but found to be suppressed in ER positive breast carcinomas ... ER negative carcinomas also show ID4 expression. There is a hypothesis that ID4 acts as a tumour ...
It is important to correctly identify, as it can be confused with atypical ductal hyperplasia, cribriform ductal carcinoma in ... Collagenous spherulosis, or simple spherulosis, is a benign finding in breast pathology. It is almost always an incidental ... Adenomyoepithelioma Misdiagnosis Resetkova, E.; Albarracin, C.; Sneige, N. (Jan 2006). "Collagenous spherulosis of breast: ... like in benign breast glands. The lesions are typically small (less than 50 spherules per lesion, less than 100 micrometers in ...
... comparison with matched cases of invasive ductal carcinoma of the breast". Breast. 8 (4): 188-90. doi:10.1054/brst.1999.0042. ... It accounts for 5-10% of invasive breast cancer. Rare cases of this carcinoma have been diagnosed in men (see male breast ... "Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome". Breast Cancer Res. 6 (3): R149-56. ... "Clinicopathological characteristics and survival outcomes in pleomorphic lobular breast carcinoma of the breast: a SEER ...
... has also been implicated in breast cancer and ductal carcinoma and, thus, may serve as a novel biomarker for tracking ... Suhane S, Berel D, Ramanujan VK (Sep 2011). "Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma". ...
... invasive lobular carcinoma, ductal carcinoma in situ, and invasive ductal carcinoma. A positive family history of breast cancer ... lobular carcinoma, ductal carcinoma in situ, invasive ductal carcinomas of no special type, Cowden disease, Noonan syndrome, ... One of these individuals had PB coexisting with ductal carcinoma in situ and invasive ductal carcinoma; the same PIC3K mutation ... individuals had an associated breast carcinoma at diagnoses and 68 (19%) had a family history of breast cancer. The breast ...
Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS (January 2005). "A putative human breast stem cell population is ... Blakolmer K, Jaskiewicz K, Dunsford HA, Robson SC (June 1995). "Hematopoietic stem cell markers are expressed by ductal plate ... Boulter CA, Wagner EF (March 1988). "The effects of v-src expression on the differentiation of embryonal carcinoma cells". ... March 2006). "Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma". Carcinogenesis. 27 ...
Seifert G (September 1998). "Are adenomyoepithelioma of the breast and epithelial-myoepithelial carcinoma of the salivary ... This tumour is characterised by biphasic tubular structures composed of inner ductal and outer clear myoepithelial cells. Its ... Epithelial-myoepithelial carcinoma (EMCa) is a rare malignant tumour that typically arises in a salivary gland and consists of ... Epithelial-myoepithelial carcinoma of the lung Adenomyoepithelioma Kasper HU, Mellin W, Kriegsmann J, Cheremet E, Lippert H, ...
... carcinoma, ductal MeSH C04.557.470. - carcinoma, ductal, breast MeSH C04.557.470. - carcinoma, ... ductal MeSH C04.557.470.615.132.500 - carcinoma, ductal, breast MeSH C04.557.470.615.132.750 - carcinoma, pancreatic ductal ... breast neoplasms, male MeSH C04.588.180.390 - carcinoma, ductal, breast MeSH C04.588.180.762 - phyllodes tumor MeSH C04.588. ... pancreatic ductal MeSH C04.557.470.200.025.240 - carcinoma, endometrioid MeSH C04.557.470.200.025.255 - carcinoma, ...
2002). Yamamoto M, Bharti A, Li Y, Kufe D (May 1997). "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta ... "ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 ... Increased nuclear β-catenin levels have also been noted in basal cell carcinoma (BCC), head and neck squamous cell carcinoma ( ... ovarian carcinoma, breast cancer, lung cancer and glioblastoma. It has been estimated that approximately 10% of all tissue ...
The following features are all important in deciding on a course of treatment for any breast tumor: Size Status of surgical ... Breast cancers usually are epithelial tumors of ductal or lobular origin. ... Invasive Carcinoma. Invasive ductal carcinoma. Invasive ductal carcinoma is the most commonly diagnosed breast cancer and has a ... Ductal Carcinoma In Situ. Ductal carcinoma in situ (DCIS) is noninvasive breast cancer that is limited to the inside of the ...
Background Up to 50% of recurrences of ductal carcinoma in situ (DCIS) of the breast are associated with invasive carcinoma but ... Hypothesis I hypothesized that the risk of malignant tranformation (from normal breast to DCIS) and of invasive recurrence, ... These were related to the presence of invasive carcinoma at initial diagnosis, the histological features of DCIS and the risk ... DCIS associated with invasive carcinoma showed a profile of vascular immunostaining similar to that of pure DCIS but there were ...
Learn in-depth information on Invasive Ductal Carcinoma of Breast (NOS), its causes, symptoms, diagnosis, complications, ... Invasive Ductal Carcinoma of Breast, Carcinoma with Osteoclastic Giant Cells. *Invasive Ductal Carcinoma of Breast, Carcinoma ... Invasive Ductal Carcinoma of Breast, Carcinoma with Melanotic Features. Who gets Invasive Ductal Carcinoma of Breast (NOS)? ( ... How is Invasive Ductal Carcinoma of Breast (NOS) Diagnosed?. Invasive Ductal Carcinoma of Breast (NOS) may be diagnosed in the ...
... and at least 5 samples retrieved for histopathological evaluation which yielded Grade II invasive left breast ductal carcinoma. ... Agolah D, Ductal breast carcinoma. Case study, (Accessed on 06 Dec 2022) ... Precision Molecular Pathology of Breast Cancer. (2015) ISBN: 9781493928866 - Google Books. *Tibor Tot. Breast Cancer. (2010) ... Breast Imaging Cases. (2011) ISBN: 9780199875733 - Google Books. *Ashraf Khan, Ian O. Ellis, Andrew M. Hanby et al. ...
... of the breast associated with Poland syndrome. A skin-sparing mastectomy of the left breast with immediate reconstruction using ... We report a rare case of multi-focal ductal carcinoma in situ (DCIS) ... A Case of Ductal Carcinoma In situ of Breast with Poland Syndrome. TCM Wong, J Lim, TC Lim ... Introduction: A 51-year-old woman was diagnosed with a rare case of multi-focal ductal carcinoma in situ (DCIS) of the breast ...
Comparison of the Diagnostic Value of Mammography and Ultrasonography for Breast Ductal Carcinoma in situ, WEN XIAN CHEN, JI ... Ductal carcinoma in situ, Contrast-enhanced ultrasonography, Mammography. The incidence of ductal carcinoma in situ (DCIS) was ... Comparison of the Diagnostic Value of Mammography and Ultrasonography for Breast Ductal Carcinoma in situ. ... the diagnosis of ductal carcinoma in situ and it is of great significance for the diagnosis and treatment of ductal carcinoma ...
Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on fine-needle aspiration biopsy ... Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on fine-needle aspiration biopsy ... Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on fine-needle aspiration biopsy ... Dive into the research topics of Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on ...
Computer-Aided Heterogeneity Analysis in Breast MR Imaging Assessment of Ductal Carcinoma In Situ: Correlating Histologic Grade ... PURPOSE: To identify breast MR imaging biomarkers to predict histologic grade and receptor status of ductal carcinoma in situ ( ... Computer-Aided Heterogeneity Analysis in Breast MR Imaging Assessment of Ductal Carcinoma In Situ: Correlating Histologic Grade ... Computer-Aided Heterogeneity Analysis in Breast MR Imaging Assessment of Ductal Carcinoma In Situ: Correlating Histologic Grade ...
title = "Genetic predisposition to ductal carcinoma in situ of the breast",. abstract = "Background: Ductal carcinoma in situ ( ... Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is often associated with invasive ductal carcinoma ... Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is often associated with invasive ductal carcinoma ... Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is often associated with invasive ductal carcinoma ...
Evans, A. Ductal carcinoma in situ (DCIS): are we overdetecting it?. Breast Cancer Res 6 (Suppl 1), P23 (2004). ... Ductal carcinoma in situ (DCIS): are we overdetecting it?. *A Evans1 ... Breast Cancer Research volume 6, Article number: P23 (2004) Cite this article ... Data gathered from all the units in the National Health Service Breast Screening Programme indicate a strong correlation ...
A nationwide online survey targeted at UK breast surgeons was undertaken. The anonymous survey contained questions regarding ... there continues to be a wide variety of views amongst breast surgeons regarding the ideal management of DCIS. However, by ... There is wide variation in the management of Ductal Carcinoma In Situ (DCIS) nationwide. We aimed to investigate whether the ... A Nationwide Cross-Sectional Survey of UK Breast Surgeons Views on the Management of Ductal Carcinoma In Situ. ...
The prognostic effects of these factors and features on the development of invasive breast cancer were examined with Cox step- ... with the development of invasive breast cancer. Texture (difference entropy, p < 0.001; contrast, p < 0.001; peak ... and neither worst nor predominant nuclear grade was significantly associated with development of invasive carcinoma. Here, we ... of patients with breast ductal carcinoma in situ (DCIS) had more than one nuclear grade, ...
This study was to find genes that might increase the risk of ductal carcinoma in situ (DCIS). ... A study looking at the genetics of ductal carcinoma in situ (ICICLE). Cancer type:. Breast cancer ... This study was to find genes that might increase the risk of ductal carcinoma in situ (DCIS). ... DCIS might develop into an invasive ductal breast cancer if it isnt treated. ...
The following features are all important in deciding on a course of treatment for any breast tumor: Size Status of surgical ... Breast cancers usually are epithelial tumors of ductal or lobular origin. ... Invasive Carcinoma. Invasive ductal carcinoma. Invasive ductal carcinoma is the most commonly diagnosed breast cancer and has a ... Ductal Carcinoma In Situ. Ductal carcinoma in situ (DCIS) is noninvasive breast cancer that is limited to the inside of the ...
Khanna M, Manjari M, Khanna A. Lactating adenoma with infiltrating ductal carcinoma breast in a pregnant woman. Indian Journal ...
Ductal carcinoma in situ (DCIS) is a breast disease that may lead to invasive breast cancer. The cancer cells are only in the ... Invasive ductal carcinoma. The cancer cells begin in the ducts and then grow outside the ducts into other parts of the breast ... Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The ... Breast cancer can begin in different parts of the breast. A breast is made up of three main parts: lobules, ducts, and ...
There are two main types of breast cancer: ... Breast cancer is cancer that starts in the tissues of the ... Carcinoma - ductal; Carcinoma - lobular; DCIS; LCIS; HER2-positive breast cancer; ER-positive breast cancer; Ductal carcinoma ... Breast cancer is cancer that starts in the tissues of the breast. There are two main types of breast cancer:. *Ductal carcinoma ... In most cases, stage IV breast cancer cannot be cured.. *Stage 0 and ductal carcinoma: Lumpectomy plus radiation or mastectomy ...
... prospectively defined a low-risk subset of ductal carcinoma in situ (DCIS) patients where radiation therapy was omitted after ... CONCLUSIONS: Adjuvant whole breast radiation therapy reduced the rate of local recurrence by more than 70% in patients with ... The purpose of the study was to determine the ipsilateral breast tumor recurrence (IBTR) in DCIS patients who met the criteria ... All patients were treated with lumpectomy and whole breast RT with a boost to a median total tumor bed dose of 6400 cGy. ...
... ... woman with advanced stage invasive ductal breast carcinoma. The ... However since there are very few models that meet all the criteria that BT-474 does (human breast carcinoma that is ER+, PR+ ... Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16): 3131-3141.. ... Optimization of our BT-474 breast cancer model in NSG mice has been a significant advancement of our validated breast tumor ...
Breast Ductal Carcinoma in Situ. Precursor to Invasive Breast Cancer. *William B. Coleman ... Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. *Sharon Nofech-Mozes, ... Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ. *Bethany N. Hannafon, ... Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. *Souzan Sanati ...
... women with ductal carcinoma in situ without microinvasion: - Group II - women with ductal carcinoma in situ with microinvasion ... Thcre was a retrospectivc analysis performed on 44 women operated on for ductal carcinoma in situ of the breast betwecn January ... Title: Ductal carcinoma in situ of the breast : morphology and clinical implications ... B. Morphology of ductal carcinoma in situ depends on patients age. C. Microcalcification is the most common symptom of DCIS in ...
Surgery is considered the primary treatment for breast cancer. Goals include complete resection of the primary tumor, with ... Breast cancer. Infiltrating ductal carcinoma. Low-grade carcinoma with well-developed glands invading the fibrous stroma. ... inflammatory breast cancer, or ductal carcinoma in situ (when breast-conserving surgery is planned) or who are pregnant ... SLN biopsy may be offered to women who have operable breast cancer and multicentric tumors, women with ductal carcinoma in situ ...
... de_DE. ... Breast MRI of pure ductal carcinoma in situ: Sensitivity of diagnosis and influence of lesion characteristics. DSpace ...
Noninvasive breast cancer often has no signs or symptoms. Find out how doctors diagnose DCIS and learn about treatment, ... Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in the breast. ... Stereotactic breast biopsy During a stereotactic breast biopsy, your breast will be firmly compressed between two plates. ... Ductal carcinoma in situ (DCIS). Medically reviewed by Last updated on May 18, 2022. ...
Like ductal carcinoma in situ, it begins in the milk ducts of the breast. But unlike DCIS, invasive ductal carcinoma is not ... Left Breast mass, retroareolar- invasive ductal carcinoma. Invasive ductal carcinoma, no special type. in-situ component- not ... Left Breast mass, retroareolar- invasive ductal carcinoma. Invasive ductal carcinoma, no special type. in-situ component- not ... One out of every five new breast cancer diagnoses each year is ductal carcinoma in situ (DCIS). This is an uncontrolled growth ...
She is Lead Breast Pathologist at Guys & St Thomas Hospitals. ... Sarah Pinder is Chair of Breast Pathology, in the School of ... Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Grand Challenge ... Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: ... Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. Maxwell, A. J., Hilton ...
N0 breast cancer were treated with breast-conserving surgery and breast irradiation, between January 1, 1985, and December 31, ... For patients with positive resection margins, the time intervals from breast surgery to breast irradiation used for analysis ... Patients with positive resection margins have higher local recurrence rates that become apparent when breast irradiation is ... The aim of this study was to determine the effect of timing of radiotherapy after conservative breast surgery on local ...
... of enlargement of the previously stable mass underwent imaging assessment and biopsy which revealed ductal carcinoma in situ ... Ductal carcinoma in situ (DCIS) in breast fibroadenoma. Access & Citations. * 4048 Article Accesses. ...
Ductal carcinoma in situ, or DCIS, is a form of pre-cancer in which a carcinoma, or abnormal growth of cells, is found in the ... However, in some cases, DCIS can become a more aggressive form of cancer called invasive ductal carcinoma, or IDC. ... In fact, deaths from DCIS as well as other types of breast cancer have been declining in recent years due to earlier detection ... In situ means that the abnormal cells have not spread or invaded other breast tissues outside of the duct. In other words, ...
There are two main types of male breast cancer: infiltrating (or invasive) breast carcinoma and ductal carcinoma in situ. ... Breast Carcinoma. There are two types of invasive breast cancer. Invasive ductal carcinoma (IDC) starts in the breast duct and ... Ductal Carcinoma in Situ. Also known as intraductal carcinoma, ductal carcinoma in situ (DCIS) is a preinvasive cancer. Cancer ... IDC is the most common type of breast cancer in men.. Invasive lobular carcinoma is much less common in men. It originates in ...
  • Ductal carcinoma in situ (DCIS) is noninvasive breast cancer that is limited to the inside of the ducts of the breast. (
  • Lobular carcinoma in situ (LCIS) is noninvasive breast cancer that arises from the lobule at the terminal end of the duct and shows a rather diffuse distribution throughout the breast, which explains its presentation as a nonpalpable mass in most cases (see the images below). (
  • Background Up to 50% of recurrences of ductal carcinoma in situ (DCIS) of the breast are associated with invasive carcinoma but no pathological or molecular features have yet been found to predict for the development of invasive disease. (
  • Methodology I investigated to see whether changes in vasculature are related to the progression of in situ to invasive carcinoma and if so, which factors may be important in this change. (
  • A 51-year-old woman was diagnosed with a rare case of multi-focal ductal carcinoma in situ (DCIS) of the breast associated with Poland syndrome. (
  • We report a rare case of multi-focal ductal carcinoma in situ (DCIS) of the breast associated with Poland syndrome. (
  • To evaluate the diagnostic value and imaging features of mammography and contrast-enhanced ultrasonography in breast ductal carcinoma in situ, 60 patients with 62 lesions were selected from 80 patients with ductal carcinoma in situ who were surgically treated and pathologically diagnosed in Huzhou Central Hospital from June 2017 to June 2019. (
  • Contrast-enhanced ultrasound could provide a rapid, reliable, and accurate diagnostic basis for the diagnosis of ductal carcinoma in situ and it is of great significance for the diagnosis and treatment of ductal carcinoma in situ in the clinic. (
  • Mammography and contrast-enhanced ultrasound can be combined to improve the accuracy and sensitivity of early diagnosis and screening of ductal carcinoma in situ, which is worthy of clinical application. (
  • The incidence of ductal carcinoma in situ (DCIS) was high in the breast diseases and its common clinical symptoms were mainly characterized by the breast mass, nipple discharge, and pain[ 1 ]. (
  • With the use of fine-needle aspiration biopsy to evaluate nonpalpable breast lesions, an increasing number of cases of ductal carcinoma in situ (DCIS) are encountered. (
  • Chou S-HS, Gombos EC, Chikarmane SA, Giess CS, Jayender J. Computer-Aided Heterogeneity Analysis in Breast MR Imaging Assessment of Ductal Carcinoma In Situ: Correlating Histologic Grade and Receptor Status . (
  • PURPOSE: To identify breast MR imaging biomarkers to predict histologic grade and receptor status of ductal carcinoma in situ (DCIS). (
  • Background: Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. (
  • Ductal carcinoma in situ (DCIS): are we overdetecting it? (
  • A Nationwide Cross-Sectional Survey of UK Breast Surgeons' Views on the Management of Ductal Carcinoma In Situ. (
  • There is wide variation in the management of Ductal Carcinoma In Situ (DCIS) nationwide. (
  • Previously, 50% of patients with breast ductal carcinoma in situ ( DCIS) had more than one nuclear grade, and neither worst nor predominant nuclear grade was significantly associated with development of invasive carcinoma. (
  • Ductal carcinoma in situ (DCIS) of the breast is being diagnosed more frequently as a result of mammographic screening. (
  • Ductal carcinoma in situ (DCIS) is a breast disease that may lead to invasive breast cancer. (
  • This study was to find genes that might increase the risk of ductal carcinoma in situ (DCIS). (
  • Ductal carcinoma in situ treated with breast-conserving surgery and ra" by Sabin B. Motwani, Sharad Goyal et al. (
  • BACKGROUND: Recent data from Eastern Cooperative Oncology Group (ECOG) Study 5194 (E5194) prospectively defined a low-risk subset of ductal carcinoma in situ (DCIS) patients where radiation therapy was omitted after lumpectomy alone. (
  • Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in the breast. (
  • One out of every five new breast cancer diagnoses each year is ductal carcinoma in situ (DCIS). (
  • Like ductal carcinoma in situ, it begins in the milk ducts of the breast. (
  • She is a founder member of Sloane Project Steering Group and her translational research interests are focused particularly on in situ breast carcinoma. (
  • Ductal carcinoma in situ, or DCIS, is a form of pre-cancer in which a carcinoma, or abnormal growth of cells, is found in the lining of a breast duct. (
  • In situ' means that the abnormal cells have not spread or invaded other breast tissues outside of the duct. (
  • A prospective study of weight gain in women diagnosed with early-stage invasive breast cancer, ductal carcinoma in situ, and women without breast cancer. (
  • We therefore examined factors associated with =5% weight gain over 2-year follow-up of a cohort of newly diagnosed early-stage invasive breast cancer (EIBC) and ductal carcinoma in situ (DCIS) patients and age-matched controls without a breast cancer history. (
  • Also known as intraductal carcinoma, ductal carcinoma in situ (DCIS) is a preinvasive cancer. (
  • If ductal carcinoma in situ (DCIS) is diagnosed by histological examination such as core needle biopsy or vacuum-assisted biopsy (VAB), invasion is often found by removing the entire tumor and performing pathological examination. (
  • This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. (
  • It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ. (
  • PRIMARY OBJECTIVES: I. To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral ductal carcinoma in situ (IIBCR-SCR-DCIS) in women with human epidermal growth factor receptor 2 (HER2)-positive DCIS resected by lumpectomy. (
  • PURPOSE: Severe fatigue after treatment of ductal carcinoma in situ (DCIS) has not been studied before. (
  • Lobular carcinoma in situ does not require treatment. (
  • Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy. (
  • A total of 2963 were diagnosed with invasive cancer or ductal carcinoma in situ within 12 months of screening. (
  • Ductal carcinoma can remain within the ducts as a noninvasive cancer (ductal carcinoma in situ), or it can break out of the ducts (invasive ductal carcinoma). (
  • If you've had a breast biopsy that found lobular carcinoma in situ (LCIS) or atypical hyperplasia of the breast, you have an increased risk of breast cancer. (
  • The Oncotype DX Breast DCIS test, examines 12 genes in a patient's ductal carcinoma in situ to determine recurrence risk and whether the patient might benefit from radiation. (
  • The most common kinds of breast cancer in men are the same kinds in women-invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ. (
  • In situ ductal carcinoma was not found. (
  • O carcinoma ductal in situ não foi encontrado. (
  • Ductal carcinoma in situ is a common type of breast cancer. (
  • lobular carcinoma in situ is not a true cancer. (
  • Adequately treated cervical carcinoma in situ without evidence of disease. (
  • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ. (
  • Ductal carcinoma in situ: This is also referred to as stage breast cancer. (
  • Lobular carcinoma in situ: This is a precancerous illness where there are usually abnormal cells at the lobules of the breast. (
  • Researchers at Kaiser Permanente have found that patients with a very early form of breast cancer (ductal carcinoma in situ or DCIS) who have higher mammographic density may be at increased risk for subsequent breast cancer, especially in the breast opposite to the one with the initial cancer. (
  • Information on mammographic density may help with treatment decisions for ductal carcinoma in situ patients," she said. (
  • This study in Iraq used in situ hybridization to detect the frequency and genotyping of HPV in tissue specimens from 129 patients diagnosed with malignant breast cancer, 24 with benign breast tumours and 20 healthy controls. (
  • L'étude menée en Iraq a utilisé la méthode d'hybridation in situ pour déterminer la fréquence du papillomavirus humain et pour son génotypage dans les échantillons de tissus prélevés auprès de 129 patientes ayant reçu un diagnostic de cancer du sein malin, de 24 patientes porteuses d'une tumeur du sein bénigne et de 20 femmes témoins en bonne santé. (
  • Lobular carcinoma in situ (LCIS) is a type of breast change that is sometimes seen when a breast biopsy is done. (
  • Carcinoma in situ (CIS) is a group of abnormal cells that are found only in the place where they first formed in the body (see left panel). (
  • Lobular carcinoma may be either lobular carcinoma in situ (LCIS) or invasive lobular carcinoma. (
  • What is in situ carcinoma of the breast? (
  • There are 2 types of breast carcinoma in situ: ductal carcinoma in situ (DCIS) and Paget disease of the nipple. (
  • Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form in the milk glands (lobules) in the breast. (
  • Lobular carcinoma in situ is a rare disease that increases your risk for developing breast cancer. (
  • Does carcinoma in situ mean cancer? (
  • Carcinoma in situ refers to cancer in which abnormal cells have not spread beyond where they first formed. (
  • Is carcinoma in situ a tumor? (
  • Ductal carcinoma in situ pronunciation with meanings, synonyms, antonyms, translations, sentences and more Correct way to pronounce mirlo in Spanish is? (
  • What are symptoms of ductal carcinoma in situ? (
  • Ductal carcinoma in situ does not have specific symptoms such a lump or breast pain. (
  • Is carcinoma in situ considered internal cancer? (
  • There are two types of CIS, ductal carcinoma in situ and lobar carcinoma in situ (DCIS & LCIS), neither of which are cancer. (
  • Women diagnosed with ductal carcinoma in situ may be candidates for breast-conserving surgery or mastectomy. (
  • According to the NCCN guidelines, a sentinel node biopsy may be considered in women with ductal carcinoma in situ treated with mastectomy. (
  • They'll show up on a mammogram, sometimes, and you can take those out, and they'll be what's called ductal carcinoma in situ . (
  • Breast cancers include invasive breast cancer, ductal carcinoma in situ (DCIS), and other in situ excluding lobular carcinoma in situ (LCIS). (
  • We report a case of a 45-year-old woman with a history of local ductal carcinoma in situ (DCIS) of the breast, who presented with muscle tremors and general weakness. (
  • Results CSC prevalence We analyzed CD44 and CD24 expression to identify the CSC phenotype (CD44+CD24?low) in the invasive breast cancer tissues, carcinoma in situ, and the metastatic lymph node lesion. (
  • CD44+CD24?low subpopulation tumor cell was detected in the in situ carcinomas and in the invasive tumor cells as well as in the metastatic lymph node lesions and in the normal epithelium, when the latter were observable in the examined sections. (
  • Ductal carcinoma in situ (DCIS) component was recognized in 38.3% (64/167). (
  • was detected in the in situ carcinomas and in.1997;33:787C91. (
  • Lobular carcinoma in situ (LCIS) typically display monomorphic, loosely cohesive, slightly enlarged and evenly spaced cells that fill acini. (
  • The main differential diagnosis is ductal carcinoma in situ (DCIS) . (
  • E-cadherin is negative in lobular carcinoma in situ (LCIS). (
  • p120 has a cytoplasmic staining in lobular carcinoma in situ (LCIS). (
  • In contrast, both E-cadherin (left image below) and p120 (right) have a membranous staining pattern in ductal carcinoma in situ (DCIS). (
  • Women with low-grade DCIS are at higher risk of developing invasive breast cancer than women without DCIS, but are less likely to have a recurrence of the breast carcinoma or to develop new cancers than women with higher-grade DCIS. (
  • Low-grade DCIS cells appear very much like normal breast cells or atypical ductal hyperplasia cells. (
  • [ 1 ] is an attempt to objectively determine the aggressiveness of DCIS and the probability that local recurrence will occur after breast-conserving therapy (surgery). (
  • Hypothesis I hypothesized that the risk of malignant tranformation (from normal breast to DCIS) and of invasive recurrence, following initial diagnosis and treatment of DCIS, is associated with the extent and pattern of periductal vascularity. (
  • These were related to the presence of invasive carcinoma at initial diagnosis, the histological features of DCIS and the risk of recurrence. (
  • DCIS associated with invasive carcinoma showed a profile of vascular immunostaining similar to that of pure DCIS but there were statistically significantly greater numbers of CDS4+ and CD141+ vessels and fewer staining for vWF. (
  • Conclusions Blood vessels surrounding DCIS appear to have a different immunophenotype when compared with blood vessels surrounding normal breast lobules. (
  • This is the first reported case of DCIS of the breast with Poland syndrome. (
  • Studies have found that about 50 % of the breast DCIS patients were associated with nipple discharge and accompanied by pain from breast inflammation and ductal ectasia[ 2 ]. (
  • In recent years, the advantages of the contrast-enhanced ultrasonography in the early screening and diagnosis of the breast DCIS have become increasingly prominent, mainly because the ultrasound has the advantages of convenient, noninvasive, no side effects, economic, real-time dynamic. (
  • Inclusion criteria were, unilateral, only DCIS, no invasive components, no previous breast cancer or other malignant tumours, received mammography and bilateral breast ultrasound evaluation, no previous chemotherapy or radiotherapy, no pregnancy or lactation. (
  • The authors previously demonstrated that it is not possible to distinguish definitively between DCIS and invasive ductal carcinoma on fine-needle aspiration biopsy. (
  • To determine whether DCIS could be separated from atypical ductal hyperplasia (ADH), the authors identified all cases of exclusive DCIS or ADH with fine-needle aspiration biopsy before surgery. (
  • Results: Most (67 %) of the 76 known breast cancer predisposition loci showed an association with DCIS in the same direction as previously reported for invasive breast cancer. (
  • Approximately 60% of screen-detected DCIS is high grade and in the vast majority of these patients adequate treatment will be preventing the occurrence of high grade invasive breast cancer. (
  • Data gathered from all the units in the National Health Service Breast Screening Programme indicate a strong correlation between the detection of DCIS and the detection of small invasive cancers. (
  • Our survey reaffirms that, irrespective of national guidelines and attempts at uniformity, there continues to be a wide variety of views amongst breast surgeons regarding the ideal management of DCIS. (
  • DCIS is when some cells inside the tubes in the breast (the ducts) have started to turn into cancer cells. (
  • DCIS might develop into an invasive ductal breast cancer if it isn't treated. (
  • They found out more about their family history to see if any of their relatives had also had DCIS or breast cancer. (
  • The study team found this study provides the strongest evidence so far that DCIS like invasive breast cancer can be genetic. (
  • And that many of the genetic changes that cause invasive breast cancer also cause DCIS. (
  • Researchers looked at the data of 38 studies of breast cancer and DCIS. (
  • They found that most of the 76 known genetic changes that increase the risk of invasive breast cancer also increase the risk of DCIS. (
  • They found that there was a link between the genes that increase the risk of ER positive breast cancer and ER positive DCIS. (
  • The study team didn't find any genetic changes that only increased the risk of DCIS and not invasive breast cancer. (
  • The team concluded that this study gives the strongest evidence to date that there is a shared genetic cause of DCIS and invasive breast cancer. (
  • Studies with larger numbers need to be done to determine if there are particular genetic changes that increase the risk of DCIS and not invasive breast cancer. (
  • The purpose of the study was to determine the ipsilateral breast tumor recurrence (IBTR) in DCIS patients who met the criteria of E5194 treated with lumpectomy and adjuvant whole breast radiation therapy (RT). (
  • DCIS is considered the earliest form of breast cancer. (
  • DCIS is usually found during a mammogram done as part of breast cancer screening or to investigate a breast lump. (
  • DCIS forms when genetic mutations occur in the DNA of breast duct cells. (
  • DCIS is most often discovered during a mammogram used to screen for breast cancer. (
  • But unlike DCIS, invasive ductal carcinoma is not contained. (
  • However, in some cases, DCIS can become a more aggressive form of cancer called invasive ductal carcinoma, or IDC. (
  • Although DCIS is not usually detected during a breast physical exam, the frequency of the diagnosis of DCIS has increased dramatically in recent years, as the use of screening mammography has become more common. (
  • In fact, deaths from DCIS as well as other types of breast cancer have been declining in recent years due to earlier detection and treatment. (
  • This study suggests that tobacco components may have an influence on the progression from DCIS to invasive ductal carcinoma. (
  • Determine the value of trastuzumab given during RT compared to RT alone in improving the incidence of contralateral invasive or DCIS breast cancer. (
  • The current study examined (i) the prevalence of severe fatigue in DCIS patients versus breast cancer survivors (BCS) and healthy controls (HC), (ii) quality of life and functioning of severely versus non-severely fatigued DCIS patients and BCS, and (iii) the association of fatigue with psychosocial and behavioral factors in DCIS patients. (
  • Results of a previous study showed that patients with DCIS who had higher mammographic density had about two to three times increased risk for a second breast cancer. (
  • To confirm her earlier findings, Laurel A. Habel, Ph.D., research scientist at Kaiser Permanente's Division of Research, and colleagues conducted a larger cohort study that consisted of 935 women diagnosed with DCIS who were treated with breast-conserving surgery (i.e., not a mastectomy) between 1990 and 1997 at Kaiser Permanente of Northern California. (
  • DCIS most commonly shows up on a mammogram as new calcium deposits, but not always - sometimes, a distortion of the breast tissue on the scan can be a sign of DCIS. (
  • An additional 40 women, not included above, were diagnosed with CIS (other), DCIS, or invasive breast cancer through the NBCCEDP following a mammogram funded through another source. (
  • Increased numbers of both CSCs of CD44+CD24?low phenotype and cells underwent EMT in DCIS lesion might be an initial step in the stromal invasion and propagation of breast cancer, and occurrence of EMT in the breast tumor associated with high prevalence of CSCs, promoting tumor invasiveness and metastasis. (
  • tumor cells in the invasive breast cancer tissues, DCIS, and the metastatic lymph node lesion. (
  • It is a type of cancer in which certain cells in the breast become abnormal, grow uncontrollably, and form a malignant mass (tumor). (
  • The prognosis of Invasive Ductal Carcinoma of Breast (NOS) depends on the stage of the tumor and response to treatment, since it is an invasive type of malignancy. (
  • A solidly fixed, relatively circumferential left breast subareolar solid tumor with distinctly spiculated outer borders with the spicules visibly non paralleling the breast tissue planes is noted. (
  • The goals of breast cancer surgery include the complete resection of the primary tumor, with negative margins to reduce the risk of local recurrences, and pathologic staging of the tumor and axillary lymph nodes to provide necessary prognostic information. (
  • The American Type Culture Collection (ATCC) reports that the BT-474 cell line was originally established in 1978 by E. Y. Lasfargues, who obtained a tumor biopsy from a 60-year-old woman with advanced stage invasive ductal breast carcinoma. (
  • Stage III breast cancer typically requires induction chemotherapy to down-size the tumor to facilitate breast-conserving surgery. (
  • Breast cancer prognosis and treatment options are generally based on tumor-node-metastasis staging. (
  • 9 ] Genes other than BRCA may also be involved in predisposition to male breast cancer, including mutations in the PTEN tumor suppressor gene, TP53 mutations (Li-Fraumeni syndrome), PALB2 mutations, and mismatch repair mutations associated with hereditary nonpolyposis colorectal cancer (Lynch syndrome). (
  • Infiltrating ductal cancer is the most common tumor type of breast cancer in men, while invasive lobular carcinoma is very rare. (
  • Investigation of correlation between breast parenchymal density and prognosis, tumor biology, reoperation rates, and prognostic factors found increased breast density seems to have an effect on indicators of poor prognosis. (
  • Additionally, to treat a large tumor (measuring more than 1 centimeter in diameter) or cancer that has spread beyond the breast tissue and lymph nodes, a physician might recommend a systemic treatment, such as chemotherapy or hormonal therapy, to destroy cancerous cells or shrink the tumor prior to surgery. (
  • Lumpectomy - A surgeon removes a breast tumor along with some surrounding healthy tissue. (
  • Participating facilities at 5 U.S. Breast Cancer Surveillance Consortium breast imaging registries with linkages to pathology databases and tumor registries. (
  • Tumor-associated antigens (TAAs) are considered as a reliable indicator of breast cancer. (
  • Furthermore, in this chapter we aim to discuss the early events that cause a normal breast epithelial cell to initiate the process of tumor formation and delineate them from later stage insults to the cell that cause it to progress to advanced metastatic disease. (
  • Once you've been diagnosed with breast cancer, your doctor will review your pathology report and the results of any imaging tests to understand the specifics of your tumor. (
  • Using a tissue sample from your breast biopsy or using your tumor if you've already undergone surgery, your medical team determines your breast cancer type. (
  • Examples of sarcomas that can occur in the breast include phyllodes tumor and angiosarcoma. (
  • Rather, they are to examine the genetic makeup of the breast tumor to get a sense of the risk that the cancer might recur, whether in the breast or elsewhere, and from there, determine if chemotherapy would be the most effective post-surgery therapy option. (
  • BluePrint®, a breast cancer genomic test from the developers of MammaPrint®, is intended for assaying a tumor before its removal. (
  • Breast cancer is a type of malignant tumor (can spread from one organ to another) of the breast tissue. (
  • Breast cancer is a malignant tumor that develops in the mammary gland, more especially in the inner lining of the milk ducts. (
  • Patients with an extensive intraductal tumor or invasive lobular carcinoma should be excluded if the goal is complete tumor ablation. (
  • If you feel a tumor, the first sign can be a new lump in your breast, which wasn't there before. (
  • chemotherapy prior to surgery for invasive cancer) and is widely used to provide improved surgical outcomes, recurrence free survival and overall survival in certain subtypes of breast cancer, with the additional potential benefit that reduced tumor volume during treatment may allow for more conservative surgery. (
  • The increased numbers of small cancers detected at mammography screening allow breast-conserving surgery (BCS) for many women, underscoring the importance of accurate assessment of tumor extent. (
  • Traditional breast cancer treatment is determined by two major factors: tumor histology, assessed by classifications based on grade and morphology, and the TNM staging method, based on cancer size, nodal status, and presence or absence of distant metastases. (
  • 1 Breast MRI provides superior sensitivity and accuracy in determining the tumor burden in patients with newly diagnosed breast cancer. (
  • The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. (
  • High expression of MxA in tumor cells was associated with high levels of TILs in HER2-positive breast cancers. (
  • This study aimed to report and discuss the challenging differential diagnosis between a primary tumor of sweat glands and cutaneous metastasis of mammary carcinoma using anatomopathological and imaging diagnostic resources available today. (
  • The findings show the challenge in differentiating a primary tumor of the sweat gland from a metastatic cutaneous tumor of mammary carcinoma, even with the immunohistochemical resources currently available. (
  • occurrence of EMT in the breast tumor associated with high prevalence of CSCs, promoting tumor invasiveness and metastasis. (
  • Breast cancer. (
  • Breast cancer is the most common type of cancer diagnosed in women. (
  • Invasive Ductal Carcinoma of Breast (NOS) is a very common type of breast cancer. (
  • Precision Molecular Pathology of Breast Cancer. (
  • Breast Cancer Research , 18 (1), [22]. (
  • Breast Cancer Res 6 (Suppl 1), P23 (2004). (
  • The prognostic effects of these factors and features on the development of invasive breast cancer were examined with Cox step-wise multivariate regression. (
  • In multivariate assessments, image analysis nuclear features had significant prognostic associations (p ≤ 0.05) with the development of invasive breast cancer. (
  • What Is Breast Cancer? (
  • Breast cancer is a disease in which cells in the breast grow out of control. (
  • There are different kinds of breast cancer. (
  • The kind of breast cancer depends on which cells in the breast turn into cancer. (
  • Breast cancer can begin in different parts of the breast. (
  • Breast cancer can spread outside the breast through blood vessels and lymph vessels. (
  • When breast cancer spreads to other parts of the body, it is said to have metastasized. (
  • The cancer cells begin in the ducts and then grow outside the ducts into other parts of the breast tissue. (
  • Cancer cells begin in the lobules and then spread from the lobules to the breast tissues that are close by. (
  • The cancer cells are only in the lining of the ducts, and have not spread to other tissues in the breast. (
  • Breast cancer is cancer that starts in the tissues of the breast. (
  • In rare cases, other kinds of breast cancer can start in other areas of the breast. (
  • Most women who develop breast cancer do not have any known risk factors or a family history. (
  • Some women are at higher risk for breast cancer because of certain genetic markers or variants that may be passed down from their parents. (
  • Certain other genes may lead to an increased risk of breast cancer. (
  • Breast implants, using antiperspirants, and wearing underwire bras do not increase the risk for breast cancer. (
  • There is also no evidence of a direct link between breast cancer and pesticides. (
  • Early breast cancer often does not cause symptoms. (
  • In men, breast cancer symptoms include breast lump and breast pain and tenderness. (
  • However, the importance of self-exams for detecting breast cancer is debatable. (
  • If your doctor learns that you do have breast cancer, more tests will be done. (
  • Breast cancer stages range from 0 to IV. (
  • Surgery is considered the primary treatment for breast cancer, with many early stage patients being cured with surgery alone. (
  • Several different types of operations are available for the treatment of breast cancer. (
  • For more information, see Breast Cancer and Adjuvant Therapy for Breast Cancer . (
  • The American Society of Clinical Oncology (ASCO) released updated guidelines on the use of lymph node dissection and biopsy for patients with early stage breast cancer. (
  • This information was critical in linking the BT-474 model used in preclinical breast cancer research to real patients with the same genetic profile. (
  • According to the American Association of Cancer Research, about 80% of all breast cancer patients are ER positive and ~65% are PR positive. (
  • Patients with breast cancer that is both ER and PR positive are more likely to respond to hormone therapy. (
  • The connection between the BT-474 preclinical model and patient biomarkers, coupled with the dire need for continual advancements in breast cancer treatment, made this model highly desirable for both in vitro and in vivo research. (
  • The issue with BT-474 (and several other breast cancer models) is that it is notoriously problematic to work with in vivo. (
  • Ask your doctor when you should consider breast cancer screening and how often it should be repeated. (
  • Most groups recommend considering routine breast cancer screening beginning in your 40s. (
  • This cancer is noninvasive and has not yet made it to breast tissue outside of the ducts. (
  • She Chairs the National Coordinating Committee for Breast Pathology (NCCBP) for the Royal College of Pathologists/UK NHS Breast Screening Programme (BSP) and is a member of several other BSP committees, such as the Advisory Committee for Breast Cancer Screening and the Research Advisory Committee. (
  • Methods and materials: A total of 568 patients with T1 and T2, N0 breast cancer were treated with breast-conserving surgery and breast irradiation, between January 1, 1985, and December 31, 1992, at the London Regional Cancer Centre. (
  • Background: Weight gain after breast cancer has been associated with recurrence and mortality. (
  • Studies are necessary to elucidate mechanisms of weight gain in early-stage breast cancer survivors. (
  • Any type of breast cancer that occurs in women can also affect men. (
  • IDC is the most common type of breast cancer in men. (
  • Cancer cells are contained in the breast ducts, but they do not invade the breast's fatty tissue or spread outside the breast. (
  • Counting of mitotic cells has been shown to be of prognostic value in breast cancer in different retrospective studies. (
  • This paper describes the influence of resolution on automatic recognition by image processing of mitotic cells in Feulgen stained breast cancer sections. (
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None. (
  • Like all forms of cancer , breast cancer is made of unusual cells that grow out of control. (
  • Breast cancer usually begins either in your glands that make milk (called lobular carcinoma ), or the ducts that carry it to the nipple (called ductal carcinoma ). (
  • The cancer may grow and invade tissue around your breast, such as your skin or chest wall. (
  • Different types of breast cancer grow and spread at different rates. (
  • Who Gets Breast Cancer? (
  • Men can get breast cancer too, but they account for less than 1% of all breast cancer cases. (
  • Among women, breast cancer is the most second most common cancer diagnosed, after skin cancer, and the second leading cause of cancer deaths, after lung cancer . (
  • On average, 1 in 8 women will develop breast cancer in their lifetimes. (
  • About two-thirds of women with breast cancer are 55 or older. (
  • Fortunately, breast cancer is very treatable if you spot it early. (
  • Localized cancer (meaning it hasn't spread outside your breast) can usually be treated before it spreads. (
  • Read more about the less-sommon signs of breast cancer . (
  • It isn't a true cancer, but it means you're more likely to get breast cancer later. (
  • Watch this video [below] now to hear this inspiring breast cancer survivor story. (
  • Smoking is a risk factor for carcinogenesis in various carcinomas, including breast cancer. (
  • Dr. Williams works at Sutter Oncology & Hematology in Sacramento, CA with other offices in Davis, CA. They frequently treat conditions like Breast Cancer along with other conditions at varying frequencies. (
  • See related handout on breast cancer treatment , written by the authors of this article. (
  • Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment. (
  • In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2). (
  • Anthracycline- and taxane-containing chemotherapeutic regimens are active against breast cancer. (
  • Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breast-conserving surgery, as well as axillary lymph node dissection and chest wall radiation. (
  • Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment. (
  • Breast cancer is the second most common cause of cancer mortality in women in the United States. (
  • 2 Breast cancer treatments continue to evolve, and although family physicians do not generally make primary decisions about these therapies, understanding their rationale and underlying evidence can help with the care of their patients during and after cancer treatment. (
  • Table 1 lists the five-year survival prognosis for each stage of breast cancer. (
  • Breast-conserving surgery should be followed by radiation therapy in women with early-stage invasive or locally advanced breast cancer. (
  • Sentinel lymph node biopsy results in fewer arm complications compared with axillary lymph node dissection in the treatment of breast cancer. (
  • Axillary lymph node dissection should be performed in women who have breast cancer with clinically palpable lymph nodes. (
  • Aromatase inhibitors, with or without tamoxifen, should be offered to all postmenopausal women with hormone receptor-positive breast cancer. (
  • Chemotherapy should be offered to all women who have breast cancer with positive lymph nodes. (
  • Trastuzumab (Herceptin) should be offered to all women with breast cancer that is overexpressing ERBB2. (
  • Preoperative chemotherapy for locally advanced breast cancer increases the success of breast-conserving surgery. (
  • Family health history: Definite familial tendencies are evident, with an increased incidence seen in men who have a number of female relatives with breast cancer. (
  • Major inheritance susceptibility: An increased risk of male breast cancer has been reported in families with BRCA mutations, although the risks appear to be higher with inherited BRCA2 than with BRCA1 mutations. (
  • 7 , 8 ] At age 70 years, men have an estimated cumulative risk of breast cancer of 1.2% if they are BRCA1 mutation carriers and 6.8% if they are BRCA2 mutation carriers. (
  • 10 - 12 ] For more information, see the sections on High-Penetrance Breast and/or Gynecologic Cancer Susceptibility Genes and Management of Male Carriers of BRCA Pathogenic Variants in Genetics of Breast and Gynecologic Cancers. (
  • Breast imaging should be performed when breast cancer is suspected. (
  • The American College of Radiology recommends ultrasonography as the first imaging modality in men younger than 25 years because breast cancer is highly unlikely. (
  • For more information, see the Diagnosis section in Breast Cancer Treatment. (
  • 16 ] Breast cancer in men is almost always hormone receptor positive. (
  • In a male breast cancer series, 99% of the tumors were estrogen receptor positive, 82% were progesterone receptor positive, 9% were HER2 positive, and 0.3% were triple negative. (
  • A more advanced stage at diagnosis confers a worse prognosis for men with breast cancer. (
  • 2 , 5 , 13 ] A study found that mortality after cancer diagnosis was higher among male patients with breast cancer compared with their female counterparts. (
  • Current management of male breast cancer. (
  • Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. (
  • Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. (
  • ObjectivesTo examine the prognostic value of mammographic breast density (MBD) and mammographic features and their relationship with established prognostic factors in patients with invasive breast cancer.MethodsMammographic characteristics of 270 patients were analyzed. (
  • Mammographic breast density and characteristics of invasive breast cancer. (
  • Most of the breast cancer patients in this population had a mammographic density of B or C, indicating that breast cancer is more common in dense breasts, and future studies need to address and confirm MD and its association with subtypes and aggressiveness of breast cancer. (
  • Mammographic breast density and survival in women with invasive breast cancer. (
  • The findings reinforce the need to improve screening sensitivity among women with dense breasts and to routinely assess breast density, not only for its role as a risk factor for breast cancer but also for its potential influence on cancer prognosis. (
  • Invasive ductal carcinoma treatment is designed to address cancer cells that initially form in a milk duct and then grow beyond the walls of the duct into the surrounding breast tissue. (
  • In many cases, surgery is recommended to remove the affected breast tissue and determine whether the cancer has spread to nearby lymph nodes. (
  • Biological targeted therapy - If invasive ductal carcinoma is identified as being HER2-positive, this means that the cells produce excess amounts of a protein called HER2, which can cause the cancer to receive signals that cause it to grow very fast. (
  • In the Don & Erika Wallace Comprehensive Breast Program at Moffitt Cancer Center, we take a comprehensive, multispecialty approach to breast cancer treatment. (
  • Our fellowship-trained surgeons focus their practice exclusively on treating breast cancer patients, and we offer a complete range of treatment options in one location, including promising clinical trials. (
  • The Vn96 peptide was herein employed to recover a subset of EVs released into the media from cellular models of breast cancer. (
  • To determine factors associated with false-positive and false-negative digital mammography results, additional imaging, and biopsies among a general population of women screened for breast cancer. (
  • Some factors, such as numbers of first- and second-degree relatives with breast cancer and diagnoses associated with previous benign biopsy results, were not examined. (
  • A personalized approach to screening includes identifying individual risk factors for breast cancer. (
  • Several risk factors have been associated with breast cancer in epidemiologic studies, but most relationships are modest or inconsistent. (
  • There is something in this course for everyone - if you're a breast cancer survivor or the friend/family member of someone with this disease, this course will help you to better understand this disease, and give you ideas for questions you may want to ask your doctor. (
  • If you're a healthcare administrator wondering about how the interdisciplinary components of breast cancer care fit together, or an entrepreneur thinking about unmet needs in this space, or someone in public health interested in prevention, this course is also for you! (
  • Let's learn a bit more about inflammatory breast cancer, Paget's disease, Male breast cancer, breast cancer in pregnancy and metastatic disease. (
  • Welcome back to an introduction to breast cancer, I'm Dr. Anees Chagpar. (
  • We've learned a lot about breast cancer and the fact that we have a variety of tools in our toolbox to treat breast cancer, but remember that breast cancer is not a singular disease. (
  • The first is inflammatory breast cancer. (
  • Because this is the worst form of breast cancer that we deal with. (
  • Remember that breast cancer occurs in men too, so we'll give you a little bit of time talking about male breast cancer. (
  • We'll talk about breast cancer and pregnancy. (
  • What happens when breast cancer comes up at the most inopportune time? (
  • So starting with inflammatory breast cancer. (
  • Breast cancer is one of the most common types of cancer found in women worldwide. (
  • However, breast cancer does not always show obvious symptoms in the early stages. (
  • Hence, companies in the breast cancer diagnostics market are increasing their R&D in AI technologies to identify unmet patient needs. (
  • For instance, Paragon Biosciences LLC announced the launch of its seventh portfolio company Qlarity Imaging LLC, to gain FDA clearance for their AI system used for breast cancer diagnostics in radiology. (
  • Companies in the breast cancer diagnostics market are harnessing the advantages of AI to improve medical outcomes. (
  • Companies in the market for breast cancer diagnostics are directing their investments in developing AI systems with intuitive displays and machine learning (ML). (
  • Most types of breast cancer are treatable and survival rates are high for patients that detect cancer at an early stage. (
  • Hence, researchers in the market for breast cancer diagnostics are increasing their focus in novel methods of blood screening that are reinventing techniques for early detection of breast cancer. (
  • For instance, researchers from the University of Nottingham are innovating in new blood screening methods that can help detect breast cancer years before it gets severe. (
  • Such discoveries are bolstering market growth, as the breast cancer diagnostics market is expected to reach a revenue of ~ US$ 9 Bn by the end of 2027 . (
  • Thus, companies in the breast cancer diagnostics market should collaborate with researchers to advance in clinical studies. (
  • Nanotechnology holds promising potential for early detection of breast cancer. (
  • This technology is being highly publicized for its high sensitivity, specificity, and multiplexed measurement capacity in the breast cancer diagnostics market. (
  • The breast cancer diagnostics market is consolidated with three major players accounting for ~ 66% of the global market share. (
  • However, the reliability of nanotechnology-based cancer diagnosis in regular clinical practices is still at the nascent stage in the market for breast cancer diagnostics. (
  • Hence, companies in the market for breast cancer diagnostics are simplifying the synthesis steps and nanoprobe functionalization and are increasing R&D to launch cost-efficient ways of introducing nanotechnology-based diagnosis in clinical practices. (
  • Automated breast cancer diagnostics based on ML algorithms are bringing about a change in the market landscape. (
  • Soft computing techniques are being increasingly used to produce accurate and faster diagnosis of breast cancer amongst patients. (
  • Hence, healthcare companies in the breast cancer diagnostics market are collaborating with researchers to combine imaging techniques with ML algorithms to increase diagnosis accuracy. (
  • When we applied the sbRNA-seq analysis to the human breast cancer specimens, we identified spatial interactions between a particular population of immune cells and that of cancer-associated fibroblast cells, which were not precisely represented solely by the single-cell analysis. (
  • Breast cancer is the leading cause of cancer death in women, the second most common cancer worldwide, and the fifth most common cause of cancer-related deaths [ 1 - 3 ]. (
  • Not only are the incidence rates of breast cancer increasing, partly due to improved screening and detection techniques, but also the global burden of breast cancer exceeds all other cancers. (
  • Understand what type of breast cancer you have and how it differs from other types of breast cancer. (
  • Here's what's used to determine your breast cancer type. (
  • The type of tissue where your breast cancer arises determines how the cancer behaves and what treatments are most effective. (
  • Ductal carcinoma is the most common type of breast cancer. (
  • This type of cancer forms in the lining of a milk duct within your breast. (
  • Rarely breast cancer can begin in the connective tissue that's made up of muscles, fat and blood vessels. (
  • Some subtypes of breast cancer are named for the way they appear under the microscope. (
  • The breast cancer cells have receptors on the outside of their walls that can catch specific hormones that circulate through your body. (
  • Knowing your breast cancer is sensitive to hormones gives your doctor a better idea of how best to treat the cancer or prevent cancer from recurring. (
  • The cells of this type of breast cancer have receptors that allow them to use the hormone estrogen to grow. (
  • This type of breast cancer is sensitive to progesterone, and the cells have receptors that allow them to use this hormone to grow. (
  • Doctors are increasingly using genetic information about breast cancer cells to categorize breast cancers. (
  • Globally, breast cancer ranks first among cancers affecting women [1]. (
  • Worldwide 1 in 10 women is affected by breast cancer during their lifetime [3]. (
  • There is also the problem of benign tumours reported to be premalignant and the increased risk of developing breast cancer associated with proliferative fibrocystic diseases of the breast [4]. (
  • Fast Five Quiz: Do You Know the Differences in Breast Cancer Types and Best Practices for Treatment? (
  • Invasive ductal carcinoma is the most frequent histologic subtype of breast cancer . (
  • Learn more about breast cancer histology. (
  • Breast Cancer Surgery Timing Matters, but Is Faster Always Better? (
  • Some internet communications have addressed the link between antiperspirant use and breast cancer. (
  • A breast cancer screening programme was evaluated for approximately 10,000 women aged 35 years and older. (
  • There were 67 cases of breast cancer. (
  • Eighty-eight women presenting with locally advanced or metastatic breast cancer were treated with tamoxifen alone. (
  • This article presents the incidence of female breast cancer in the Gulf Cooperation Council [‎GCC]‎ countries and reviews the data in relation to established reproductive factors. (
  • This study used qualitative methodology to understand Iranian women's views about barriers to and factors facilitating screening for early detection of breast cancer. (
  • Carcinoma of the breast is the most prevalent cancer among Egyptian women and constitutes 29% of National Cancer Institute cases. (
  • We estimated survival rate at 9 years of all [‎470]‎ women with breast cancer diagnosed at Salah Aza‹ez Institute of Cancer in Tunis to identify the main prognosis factors. (
  • Breast cancer is the commonest type of malignancy in Iraq. (
  • The study was carried out on 721 out of a total of 5044 patients [‎14.3%]‎ presenting with palpable breast lumps that were diagnosed as cancer. (
  • Breast cancer is the most common malignant neoplasm affecting women in Bahrain. (
  • This study estimated the frequency of breast-self examination practice and its possible relation to the stage of the disease at diagnosis and patient-related delay in diagnosis among newly diagnosed breast cancer patients. (
  • Curcumol inhibits breast cancer growth via NCL/ERα36 and the PI3K/AKT pathway - Food Funct 2022 Dec 20 - 'Breast cancer (BC) is the most common malignancy worldwide. (
  • Curcumol reduced the proliferation of breast cancer cells by targeting NCL/ERα36 and inactivating the PI3K/AKT pathway' - See curcumin at . (
  • Resveratrol reverses TGF-β1-mediated invasion and metastasis of breast cancer cells via the SIRT3/AMPK/autophagy signal axis - Phytother Res 2022 Sep 9 - 'Taken together, our study provided novel insight into the anticancer effects of Resv and revealed that targeting the SIRT3/AMPK/autophagy pathway can serve as a new therapeutic target against breast cancer' - See resveratrol products at . (
  • Association of dietary intake of n-3 polyunsaturated fatty acids with breast cancer risk in pre- and postmenopausal Chinese women - Menopause 2022 Jul 26 - 'Higher intake of marine n-3 PUFAs and total n-3 PUFAs was associated with lower risk of breast cancer, with adjusted OR quartile 4 v.1 (95% confidence intervals) of 0.68 (0.55-0.84) and 0.56 (0.42-0.75), respectively. (
  • Dietary a-linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid were also inversely associated with breast cancer risk, with adjusted ORs (95% confidence intervals) of 0.51 (0.38-0.70), 0.68 (0.55-0.84), 0.68 (0.55-0.85), and 0.76 (0.61-0.94), respectively. (
  • A decreased risk of breast cancer was significantly associated with increasing n-3 PUFA intake in obese/overweight women, but not in women of normal weight. (
  • High intake of n-3 PUFAs and n-3 PUFA subtypes was associated with a lower risk of breast cancer, especially among premenopausal women and women with ER+ and/or PR+ subtype breast cancer' - See omega-3 supplements at . (
  • Vitamin D: an essential adjuvant therapeutic agent in breast cancer - J Int Med Res 2022 Jul - 'Low serum levels of vitamin D have been reported as a risk factor for breast cancer. (
  • This narrative review provides an update on the impact of vitamin D on hormone receptors, notably estrogen receptor subunits, and gives insights on possible therapeutic interventions to overcome breast cancer. (
  • In addition, evidence that supports the beneficial use of vitamin D as adjuvant treatment of breast cancer is summarized. (
  • Several studies have observed a possible modulatory effect of vitamin D or its analogues on the expression of different hormone receptors in breast cancer and increased sensitivity to tamoxifen. (
  • Vitamin D possesses anti-inflammatory and immunomodulatory effects in patients with breast cancer, and the mechanism of action of vitamin D in patients with breast cancer is discussed' - See vitamin D at . (
  • Higher efficacy of resveratrol against advanced breast cancer organoids: A comparison with that of clinically relevant drugs - Phytother Res 2022 Jun 1 - 'The lack of reliable drugs is a therapeutic challenge of advanced breast cancers (ABCs). (
  • Resveratrol (Res) exerts inhibitory effects on breast cancer cell lines and animal models, while its efficacy against individual breast cancer cases remains unknown. (
  • High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients. (
  • In the present study, we investigated the role of QSOX1 in breast cancer. (
  • CONCLUSIONS: Together, these results suggest that QSOX1 could be posited as a new biomarker of good prognosis in breast cancer and demonstrate that QSOX1 inhibits human breast cancer tumorogenesis. (
  • Breast cancer is cancer that forms in the cells of the breasts. (
  • After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. (
  • Breast cancer can occur in both men and women, but it's far more common in women. (
  • Substantial support for breast cancer awareness and research funding has helped create advances in the diagnosis and treatment of breast cancer. (
  • Breast cancer survival rates have increased, and the number of deaths associated with this disease is steadily declining, largely due to factors such as earlier detection, a new personalized approach to treatment and a better understanding of the disease. (
  • Breast and nipple changes can be a sign of breast cancer. (
  • Doctors know that breast cancer occurs when some breast cells begin to grow abnormally. (
  • Breast cancer most often begins with cells in the milk-producing ducts (invasive ductal carcinoma). (
  • Breast cancer may also begin in the glandular tissue called lobules (invasive lobular carcinoma) or in other cells or tissue within the breast. (
  • Researchers have identified hormonal, lifestyle and environmental factors that may increase your risk of breast cancer. (
  • It's likely that breast cancer is caused by a complex interaction of your genetic makeup and your environment. (
  • A number of inherited mutated genes that can increase the likelihood of breast cancer have been identified. (
  • The most well-known are breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2), both of which significantly increase the risk of both breast and ovarian cancer. (
  • If you have a strong family history of breast cancer or other cancers, your doctor may recommend a blood test to help identify specific mutations in BRCA or other genes that are being passed through your family. (
  • A breast cancer risk factor is anything that makes it more likely you'll get breast cancer. (
  • But having one or even several breast cancer risk factors doesn't necessarily mean you'll develop breast cancer. (
  • Many women who develop breast cancer have no known risk factors other than simply being women. (
  • Women are much more likely than men are to develop breast cancer. (
  • Your risk of breast cancer increases as you age. (
  • A personal history of breast cancer. (
  • If you've had breast cancer in one breast, you have an increased risk of developing cancer in the other breast. (
  • There are two main types of breast cancer:Ductal carcinoma starts in the tubes (du. (
  • Up to 70% of breast cancer patients prescribed chemotherapy after their surgeries might not need it. (
  • Help today is coming from a growing portfolio of increasingly sophisticated genomic tests that can assess recurrence risk for early-stage breast cancer patients and guide both clinicians and insurers. (
  • This informative Global Health Brief discusses breast cancer genomic testing (including the increasingly utilized MammaPrint® test) and how to effectively assess claims for these tests. (
  • Since their emergence soon after the completion of the mapping of the human genome (2003), genomic tests for breast cancer tumors have become an effective tool in medicine's cancer-fighting arsenal. (
  • Knowing a patient's potential recurrence risk for breast cancer, the most common type of cancer worldwide, can have a substantial direct impact on patient mortality and convey high benefits both to patient and insurer. (
  • Guidelines provided by groups such as the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the European Society of Medical Oncology (ESMO) recommend the use of clinical and pathological factors, including results of genomic tests, to establish patient risk of breast cancer recurrence and to guide treatment. (
  • Currently, four genomic tests (see Table 1, next page) are available for assessing breast cancer risk and the likelihood a patient might need chemotherapy. (
  • Determines candidates for chemotherapy after breast cancer surgery and who can safely avoid it without subsequent negative impact on health and survival. (
  • Predicts risk for postmenopausal women of distant recurrence of early-stage hormone receptor positive breast cancer with up to three positive lymph nodes within 10 years of diagnosis and after five years of hormone therapy. (
  • There are three additional prognostic genomic breast cancer tests, but they are not chemotherapy-focused. (
  • The Breast Cancer Index (BCI) test assays seven genes to predict recurrence risk of certain breast cancers within five to 10 years and is also used to determine at the five year mark whether to extend hormone therapy up to 10 years. (
  • Although rare, men can get breast cancer. (
  • In 2017, there were about 2,300 new cases of male breast cancer and 500 deaths. (
  • Some may be surprised at the title of this blog: Breast Cancer Among Men. (
  • Here are some questions and answers about breast cancer among men and what we learned from some recent research. (
  • How common is breast cancer in men? (
  • What are the risk factors that may increase a man's chance of getting breast cancer? (
  • Although having risk factors does not mean a man will get breast cancer, there are some things that may increase the risk like genetic mutations, a family history of breast cancer, and certain radiation and hormone therapy treatments. (
  • article on breast cancer survival among males. (
  • There isn't a lot of research out there that looks at survival among men with breast cancer, partly because it is rare. (
  • We used CDC's National Program of Cancer Registries data to examine relative survival rates of males diagnosed with breast cancer during 2007-2016. (
  • Looking at both 1- and 5-year relative survival rates among males diagnosed with breast cancer may help guide health care decisions regarding breast cancer testing and treatment among males and help to establish programs to support men at high risk of breast cancer and male breast cancer survivors. (
  • I have an identical twin brother that had breast cancer in one breast about 6 years ago. (
  • When he was diagnosed with breast cancer in his other breast in the fall of 2018 and had a second mastectomy I decided that I should have a more complete exam. (
  • I was diagnosed with breast cancer level 1 in both breast and had a double mastectomy. (
  • The only thing that I can conclude from this is that we still have a lot to learn about gene mutations as indicators for breast cancer. (
  • Earlier it was found that mostly breast cancer are found in womens. (
  • Invasive ductal carcinoma (IDC) is a type of breast cancer and the most common type of breast cancer worldwide. (
  • Another name for this type of cancer is infiltrating ductal carcinoma. (
  • ER positive breast cancer means good prognosis, as this cancerous cells are estrogen-dependent and can be treated with anti-estrogen therapy. (
  • Breast cancer is a major health problem in the people especially in the elderly women. (
  • It is the cancer of breast tissue which developed due to alteration in the genes. (
  • Breast cancer is a type of cancer that develop from the inner milk ducts or the lobules that supply the milk. (
  • Various researches shows that breast cancer is more prevalent in developed countries than developing countries and more in the women of high socio economic status. (
  • The type of breast cancer depends upon the site of cancerous tissue whether it is in the ducts of breast or in the lobules. (
  • When the caner spread to the surrounding breast tissue then it is called invasive cancer. (
  • This type of cancer firstly starts in the ducts of the breast then spread to the surrounding tissues. (
  • This type of breast cancer starts in the milk producing glands & then invades the surrounding tissues. (
  • This type of cancer that arises as ill defined thickening in the breast. (
  • This type of cancer accounts for 5% of breast cancer & arises from the capsule inside the ducts then invades the surrounding tissues. (
  • This type accounts for 3% breast cancer cases & mostly occurs in the elderly women. (
  • This type of cancer accounts for 2% of breast cancer cases & the prognosis of this type is excellent because the chances of invasion are very less. (
  • This is a peculiar type of breast cancer because the sign & symptoms are very unique. (
  • This type of breast cancer is very rare. (
  • Invasive ductal carcinoma is a type of cancer which originates in the milk ducts within the breast. (
  • Invasive lobular carcinoma is a type of cancer which originates in the milk producing lobules of the breast. (
  • Male breast cancer is a fairly rare condition and accounts for about 1% of all breast cancers types. (
  • A fairly rare form of breast cancer is called Paget's disease of the nipple. (
  • Phyllodes tumors of the breast is a very rare form of breast cancer. (
  • Recurrent breast cancer is a very frustrating and potentially dangerous form of breast cancer. (
  • In the past 2 decades, new and improved imaging technologies and the use of breast cancer screening have led to the detection of smaller and earlier-stage breast cancers. (
  • After the skin cancer, breast cancer becomes the most common type of cancer diagnosed in women, especially in the US. (
  • Continuous support from Hong Kong Cancer Fund and breast cancer awareness helps create advances in treatment and diagnosis. (
  • The survival rate of breast cancer has also intensified, and the rate of deaths has decreased, all thanks to this support, earlier detection, a better understanding of the illness, and personalized approaches to different treatments. (
  • Breast cancer may start from various parts of your breast. (
  • A few factors can cause breast cancer to develop. (
  • But exercising regularly, especially during young adulthood and adolescence, can minimize the risks of getting breast cancer. (
  • Far more imperative than modifying certain risk factors is to be vigilant about Hong Kong breast cancer screening in order to diagnose the illness and treat it early when it is easy to cure. (
  • Since it breaks through duct walls and can spread in the surrounding tissue, it makes up around 82% of all cases, making it the most common form of breast cancer. (
  • Although it is not true cancer, it may show potential for breast cancer. (
  • Pain that breast cancer causes are gradual. (
  • Anyone experiencing pain resulting from breast cancer, especially persistent or severe, must consult a good healthcare expert. (
  • In the early stages of breast cancer, the illness might cause symptoms. (
  • Women with more risk of getting breast cancer can be offered Hong Kong breast cancer screening and genetic testing for this condition. (
  • Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer. (
  • The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast cancer screening to medically underserved, low-income women aged 40–64 years. (
  • No study has evaluated NBCCEDP’s effect on breast cancer mortality. (
  • This study estimates life-years saved by NBCCEDP breast cancer screening compared with screening in the absence of NBCCEDP and with no screening. (
  • A breast cancer simulation model based on existing Cancer Intervention and Surveillance Modeling Network models was constructed. (
  • Per woman with invasive breast cancer and screen-detected invasive cancer, the Program saved 0.41 and 0.71 life-years, respectively, compared with No Program. (
  • These estimates suggest that NBCCEDP breast cancer screening has reduced mortality among medically uninsured and underinsured low-income women. (
  • Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related deaths among women in the U.S. (
  • Every year, more than 180,000 women are diagnosed with invasive breast cancer, resulting in more than 40,000 deaths. (
  • Because of mammography’s effectiveness in reducing breast cancer mortality, the U.S. Preventive Services Task Force (USPSTF), other medical organizations, and advocacy groups recommend breast cancer screening for women aged ≥40 years to receive screening mammography every 1–2 years. (
  • To reduce disparities in breast cancer mortality, the U.S. Congress passed the Breast and Cervical Cancer Mortality Prevention Act (Public Law 101-354) in 1990. (
  • This law gave the CDC the authority to establish and administer the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). (
  • The program provides free or low-cost breast cancer screening to medically underserved women aged 40–64 years with an annual income ≤250% of the federal poverty level. (
  • eISSN: 2288-5943Ultrasonography 2016;35:281-288 During the last 15 years, traditional breast cancer classifications based on histopathology have been reorganized into the luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and basal-like subtypes based on gene expression profiling. (
  • Thus, there has long been investigation into better classifications to predict outcomes for breast cancer patients. (
  • During the last 15 years, a reshuffling of breast cancer classifications has been underway, from the histopathologic type to the molecular subtype determined by microarray-based gene expression profiling. (
  • The phenotypes of breast cancer. (
  • Since 2011, the St. Gallen an immunomodulatory (IM) subtype, a mesenchymal (M) subtype, a International Expert Consensus panel has used the subtype-based mesenchymal stem-like subtype, and a luminal androgen receptor recommendation for systemic therapies for breast cancer. (
  • The M group shows the worst outcomes and the IM genetic analysis of breast cancer is not easily available in clinical group shows the best outcomes [8]. (
  • Diagnostic MRI is also used for management of residual disease following cancer excision and evaluation of suspected recurrent disease following breast conserving surgery. (
  • Breast cancer therapy relies primarily on surgical treatment when cancers are nonpalpable and detected at screening. (
  • It has been well documented that multifocal and diffuse (multicentric) breast cancer is an independent negative prognostic factor, affecting therapeutic decision-making. (
  • Breast cancer is known to be a heterogeneous disease with characteristic molecular and genetic subtypes, and although the traditional histologic classification of breast cancer offers limited prognostic value, molecular characterization, cellular markers, and imaging phenotypes of breast tumors, especially MRI, have changed the treatment landscape. (
  • Ashli Brown of Chicago was diagnosed with breast cancer in 2019 at age 29, when she was six months pregnant. (
  • I knew I had breast cancer from the reaction on the radiologist's face, even before I got the call confirming it the next day. (
  • 1 in 8 women in the U.S. will get breast cancer during her life. (
  • it is one of the strongest risk factors for primary invasive breast cancer. (
  • After reviewing medical records, evaluating mammograms at diagnosis and then calculating the risk of subsequent breast cancer events during follow-up, the researchers found that risk of second breast cancer appeared to be elevated among the women with higher density. (
  • While risk was elevated for both breasts, the increase was greatest and most consistent for the breast opposite to the one with the initial cancer," Habel said. (
  • Of the patients, 164 had a subsequent ipsilateral breast cancer (breast cancer on the original cancer-affected breast) and 59 had a new primary cancer in the other breast during follow-up. (
  • The researchers anticipated finding an increased risk of a subsequent cancer in the breast with the initial cancer, as well as in the opposite breast. (
  • In the breast cancer group, cocktail HPV genotypes were detected in 60 (46.5%) archived tissue blocks. (
  • The detection of high-oncogenic HPV genotypes in patients with breast cancer supports the hypothesis of an etiologic role for the virus in breast cancer development. (
  • breast cancer patients present in ad- mary lesions. (
  • The age associated with breast cancer devel- range of the patients was 16-72 years. (
  • Cases were assigned breast cancer specimens from diverse Najaf, Al-Qadiyisia and Al-Muthana. (
  • Cutaneous manifestations of breast cancer. (
  • In LCIS, cells that look like cancer cells are growing in the lining of the milk-producing glands (lobules) of the breast, but they don't invade through the wall of the lobules. (
  • LAH-byoo-ler KAR-sih-NOH-muh) Cancer that begins in the lobules (milk glands) of the breast. (
  • But being diagnosed with LCIS indicates that you have an increased risk of developing breast cancer. (
  • A newly-diagnosed patient talks about her experience of being diagnosed with breast cancer amidst the COVID-19 pandemic. (
  • Additionally, a high level of TILs was a prognostic factor for breast cancer, whereas the level of MxA expression had no prognostic value. (
  • The prognosis of HER2-positive breast cancer has dramatically improved because of introduction of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2. (
  • In the adjuvant setting, a high level of TILs is associated with better response to trastuzumab, and an abundant number of TILs is an independent prognostic factor in HER2-positive breast cancer [ 3 ]. (
  • Sentinel node biopsy should be considered for women with early-stage breast cancer under 70 years old . (
  • Conversely, the 2016 Society of Surgical Oncology Choosing Wisely guidelines recommended against routine sentinel lymph node biopsy in women age 70 years or older with favorable, early-stage breast cancer, as sentinel lymph node biopsy does not decrease recurrence or mortality in these patients. (
  • Sentinel node biopsy is not recommended for women with large or locally advanced disease, inflammatory breast cancer, those who have received preoperative systemic therapy, or those who are pregnant. (
  • Learn more about presentation and diagnosis of breast cancer. (
  • Fast Five Quiz: Breast Cancer Presentation and Diagnosis - Medscape - Jan 11, 2023. (
  • Breast cancer is a great example. (
  • In breast cancer, you can get a group of cells that are growing more quickly. (
  • This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. (
  • It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer. (
  • I. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin (doxorubicin hydrochloride)/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. (
  • To collect tissue and blood samples at several occasions for future biomarkers development in predicting risk of breast cancer recurrence in patients with operable node-positive or high-risk node-negative triple-negative breast cancer treated with doxorubicin/cyclophosphamide followed by paclitaxel with or without carboplatin and predicting benefit from the addition of carboplatin among these patients. (
  • 10% of their Breast Cancer Awareness cups will be donated to ABCD. (
  • Her phone rang in 1998 and Cancer Physical Therapist, Leslie Waltke, was invited to join a group of women who were determined to bring the need for emotional support to the forefront of the breast cancer community. (
  • Jim Bretzel talks about the importance of our Mentors, and how he believes the best help for someone going through breast cancer is someone who can empathize with you. (
  • Breast cancer before the age of 40 is relatively rare. (
  • When Nichole Kutmas found a lump the size of a pencil eraser, breast cancer was the last thing on her mind. (
  • Struggles with how to live your life following a breast cancer diagnosis are very real. (
  • 28 weeks pregnant Jessica Storm was diagnosed with breast cancer. (
  • Proceeds from our 2020 Date with a Plate will go to provide customized services to the thousands who will receive a breast cancer diagnosis this year. (
  • Breast cancer didn't stop with Covid-19 … and neither did you! (
  • Here's what you should know if you're on the receiving end of such a call (and it doesn't involve Dr. Google) Because my mother and maternal aunt had breast cancer, I had my first screening mammogram relatively early, at 36. (
  • In June 2016, shortly after Phyllis Eig learned she had breast cancer, her surgeon invited her to a weekly support group for newly diagnosed patients. (
  • Days later, Phyllis found herself in a room with other women who, like her, were just starting their breast cancer journeys. (
  • She was diagnosed with breast cancer. (
  • It was January 2022, and she had just been diagnosed with breast cancer. (
  • Severe hypocalcaemia in breast cancer with bone metastasis is a rare finding usually associated with an advanced stage of the disease. (
  • Severe hypocalcaemia can a presenting symptom for breast cancer relapse. (
  • Although the patient had no medical history of breast cancer, due to this result, she was referred to a mastologist, who investigated her breast nodules for the possible primary focus of the carcinoma. (
  • breast carcinoma, sweat gland carcinoma, skin cancer. (
  • Last year Margo Dominicis was diagnosed with cancer - triple negative invasive ductal carcinoma - two weeks before her 37th birthday. (
  • My breast surgeon called with the final pathology from last week's surgery and there was no residual cancer found in my lymph nodes or either breast! (
  • Margo's mother lost her battle with breast cancer. (
  • My mom died from breast cancer in 2002, and thanks to others who have participated in clinical trials since then, I had a great treatment outcome. (
  • To pay it forward, I enrolled in a clinical trial as part of my chemotherapy treatment in hopes that my participation will help other men and women diagnosed with breast cancer in the future. (
  • Table 3 shows that the CSCs were significantly associated with breast cancer classified according to hormonal receptors ( 0.029). (
  • Gestational diabetes and risk of breast cancer before age 55 years. (
  • Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort. (
  • Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. (
  • Fatigue following breast cancer is a well-known problem, with both high and persistent prevalence. (
  • The purpose of this study was to describe the long-time course of fatigue from the time of clinical suspicion of breast cancer, its dependence of patient characteristics and treatment regimens and the comparison with the course of fatigue among women with the same suspicion, but not diagnosed with breast cancer. (
  • Women with cancer were identified in the clinical database established by Danish Breast Cancer Cooperative Group (DBCG) to collect information on treatment regimen. (
  • Compared to fatigue scores before diagnosis, women with breast cancer reported a large increase of fatigue, especially in the first 6 months, followed by a slow decrease over time. (
  • Despite the long follow-up period, the women with breast cancer did not return to their level of fatigue at time of the mammography. (
  • Women without breast cancer, experienced a rapid decrease of fatigue after disproval of diagnosis followed by a steadier period. (
  • Fatigue is a persistent problem in women diagnosed with breast cancer, even several years following diagnosis and treatment. (
  • The women with breast cancer were most affected by fatigue in the first 6 months after diagnosis. (
  • Fatigue following breast cancer is a well-known and common problem, both during treatment and in the rehabilitation period. (
  • Thus, studies describing the course of fatigue before the beginning of treatment and in detail over time are rare, and knowledge about this is warranted to be able to inform women with breast cancer about the expected development of fatigue. (
  • The purpose of this study was to describe the course of fatigue following breast cancer and its association to patient characteristics in terms of treatment regimens and compare with the course of fatigue among women referred to the same diagnostic procedure, but not subsequently diagnosed with breast cancer. (
  • Pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal cancers with reported 5-year relative survival rates ranging below 10%, representing the second largest cancer-related cause of the death and with incident rates on the rise [ 1 ]. (
  • Large population studies have shown that screening with breast tomosynthesis results in improved breast cancer detection rates and fewer "call-backs," instances where women are called back from screening for additional testing because of a potentially abnormal finding. (
  • Mammograms are used as a screening tool to detect early breast cancer in women experiencing no symptoms. (
  • The National Cancer Institute (NCI) adds that women who have had breast cancer, and those who are at increased risk due to a family history of breast or ovarian cancer, should seek expert medical advice about whether they should begin screening before age 40 and the need for other types of screening. (
  • If you are at high risk for breast cancer, you may need to obtain a breast MRI in addition to your annual mammogram. (
  • See the Breast Cancer Treatment page for information about breast cancer therapy. (
  • Before scheduling a mammogram, the American Cancer Society (ACS) and other specialty organizations recommend that you discuss any new findings or problems in your breasts with your doctor. (
  • Breast cancers usually are epithelial tumors of ductal or lobular origin. (
  • Furthermore, ~20% of all breast cancers show an increase in HER2 expression, which is linked to aggressive and fast-growing tumors. (
  • RESULTS: We showed that the QSOX1 expression level is inversely correlated to the aggressiveness of breast tumors. (
  • Minimally invasive ablation techniques have been studied in early-stage small tumors with the goal of attaining efficacy similar to that of breast-conservation therapy. (
  • These oncogenes - genes that trigger most cancers when mutated - are liable for 1 / 4 of all human cancers, together with the three varieties of tumors with the best mortality charges: lung adenocarcinoma, colorectal carcinoma and ductal adenocarcinoma pancreatic. (
  • Invasive Ductal Carcinoma of Breast, Not Otherwise Specified (NOS) are invasive breast cancers, which have a tendency to be aggressive and spread. (
  • They are also able to metastasize to other parts of the body (hence known as invasive breast cancers). (
  • Most breast cancers begin in the ducts or lobules. (
  • Most breast cancers are of this type. (
  • Genes known as BRCA1 or BRCA2 are responsible for most cases of inherited breast cancers. (
  • This is why regular breast exams and mammograms are important, so cancers that don't have symptoms may be found earlier. (
  • It accounts for about 10% of invasive breast cancers. (
  • Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. (
  • Sentinel lymph node biopsy is considered for most breast cancers with clinically negative axillary lymph nodes, and it does not have the adverse effects of arm swelling and pain that are associated with axillary lymph node dissection. (
  • Most breast cancers in men present with a retroareolar mass. (
  • Not all breast cancers are the same. (
  • Breast cancers are graded on a 1 to 3 scale, with grade 3 cancers being the most different looking and considered the most aggressive. (
  • Some breast cancers are sensitive to your body's naturally occurring female hormones - estrogen and progesterone. (
  • That way, women with relatively low-risk breast cancers may avoid aggressive treatments. (
  • Tests that analyze the genetic makeup of breast cancers are available but aren't recommended in all situations. (
  • There has been one limited study of breast cancers in the south-eastern governorates [5]. (
  • Doctors estimate that about 5 to 10 percent of breast cancers are linked to gene mutations passed through generations of a family. (
  • About 1 out of every 100 breast cancers diagnosed in the United States is found in a man. (
  • Are there certain types of breast cancers that are more common in men than women? (
  • E. ER-positive, HER2-positive ductal carcinoma - these 'triple-positive' carcinomas are also called 'Luminal B'. While this would be the next best answer after A, these cancers are generally of higher grade, have a higher proliferative rate, and do not have quite as good a prognosis as Luminal A carcinomas. (
  • Furthermore, there has been a trend toward less aggressive treatment of small breast cancers, which has led to the development of less invasive alternatives than surgery with promising effectiveness, and less morbidity. (
  • There are many types of breast cancers affecting most women out there. (
  • Usually, it accounts for about 14% of all breast cancers. (
  • All types of breast cancers may cause symptoms. (
  • But you need to know that a mammogram may not be able to detect some breast cancers. (
  • Since 1991, NBCCEDP has provided more than 4.4 million breast screening examinations to more than 2.3 million women and has diagnosed more than 42,000 breast cancers. (
  • Today, we recognize that ER-positive breast cancers and ER-negative breast cancers constitute different diseases [1]. (
  • Notre objectif a ete de rapporter les criteres de diagnostic d'orientation des cancers de la thyroide dans les conditions de la pratique en zone sahelienne. (
  • Here,we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)-positive breast cancers. (
  • High levels of TILs were also associated with improved disease-free survival, particularly in HR-/HER2+ breast cancers. (
  • The prognostic significance of TILs has been determined in breast cancers, particularly human epidermal growth factor receptor 2 (HER2)-positive breast cancers and triple-negative breast cancers [ 1 ]. (
  • Based on this background, a group of investigators around the world convened to discuss the parameters and methodological issues associated with evaluating TILs in breast cancers [ 4 ] and released recommendations for their evaluation. (
  • Mammography plays a central part in early detection of breast cancers because it can show changes in the breast up to two years before a patient or physician can feel them. (
  • Research has shown that annual mammograms lead to early detection of breast cancers, when they are most curable and breast-conservation therapies are available. (
  • It is often associated with invasive ductal carcinoma (IDC), and is considered to be a non-obligate precursor of IDC. (
  • The genetic mutations cause the cells to appear abnormal, but the cells don't yet have the ability to break out of the breast duct. (
  • Instead, it grows through the duct walls and into the surrounding breast tissue. (
  • Invasive ductal carcinoma (IDC) starts in the breast duct and can then break through the duct wall, invading the fatty tissue of the breast. (
  • It breaks through the wall of the duct and invades the fatty tissue of the breast. (
  • A breast is made up of three main parts: lobules, ducts, and connective tissue. (
  • Surgery to remove cancerous tissue: A lumpectomy removes the breast lump. (
  • A total mastectomy involves complete removal of all breast tissue to the clavicle superiorly, the sternum medially, the inframammary crease inferiorly, and the anterior axillary line laterally, with en bloc resection of the pectoralis major fascia. (
  • Treatment may include breast-conserving surgery combined with radiation or surgery to remove all of the breast tissue. (
  • Each breast contains 15 to 20 lobes of glandular tissue, arranged like the petals of a daisy. (
  • During a core needle biopsy, a radiologist or surgeon uses a hollow needle to remove tissue samples from the suspicious area, sometimes guided by ultrasound (ultrasound-guided breast biopsy) or by X-ray (stereotactic breast biopsy). (
  • A sample of breast tissue in the area of concern is then removed with a needle. (
  • These have spread or invaded the surrounding breast tissue. (
  • The lymph nodes, fatty tissue, ducts, and other parts of the inside of the breast are also shown. (
  • Anatomopathological evaluation of the surgical specimens of mammoplasties may be important for the detection of breast tissue changes without previous clinical manifestations, but in our series there were no cases of malignancies, and this conduct should be discussed. (
  • These techniques would have less scarring and pain, lower costs, better preservation of breast tissue, superior cosmesis, and faster recovery time. (
  • Breast lesions can be destroyed by thermal methods, that is, by heating or freezing the tissue. (
  • There is a right and left breast, both of which have fatty tissue, ducts, and glands. (
  • The fatty tissue amount in your breast dictates the size of both. (
  • Mammographic screening, where some X-ray images of your breast are usually taken, is a common way of determining the change in the breast tissue at the early stage of the illness. (
  • The dense area consists primarily of breast ducts and connective tissue, while the non-dense tissue is mostly fat. (
  • Only 3 benign breast tumour tissues (12.5%) and none of the healthy breast tissue specimens were HPV-DNA-positive. (
  • Tissue expansion is the technique that allows the reconstruction of defects by the gradual distension of a flexible skin area, preparing it for use in solving any defect such as breast reconstruction, burns, and giant nevi1. (
  • Tissue sample from colon carcinoma, breast carcinoma or lung carcinoma. (
  • Microscopic pathology image showing infiltrating ductal carcinoma of breast. (
  • However, there were few studies on the contrast-enhanced ultrasound in the breast intraductal lesions, so this study mainly discusses the application value of contrast-enhanced ultrasound in the diagnosis of breast intraductal lesions.Clinical data of 80 patients with breast intraductal lesions diagnosed by pathology in Huzhou Central Hospital from June 2017 to June 2019 was collected. (
  • Sarah Pinder is Chair of Breast Pathology at Kings College London. (
  • ABSTRACT This study described the profile of breast pathology based on records from a reference histopathology laboratory in Yemen of 773 women with positive biopsy or mastectomy findings. (
  • After an incisional biopsy, her sample was firstly sent for anatomopathological study in a first pathology laboratory, chosen by the dermatologist, with the diagnostic hypothesis of basal cell carcinoma. (
  • Compared to mammography, sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the contrast-enhanced ultrasound in the diagnosis of benign and malignant breast ductal lesions was significantly better. (
  • How is the diagnosis of invasive ductal carcinoma made? (
  • Anatomopathological and immunohistochemical study revealed a preliminary diagnosis of breast carcinoma metastasis. (
  • New anatomopathological and immunohistochemical exams confirmed the diagnosis of breast carcinoma metastasis. (
  • It also evidenced the importance of the clinical history, the correct propaedeutics, and a detailed study of the breasts to arrive at the proper diagnosis, ruling out others possibilities. (
  • Sucheta Srivastava, M.D.. Breast - Noninvasive lobular neoplasia - LCIS classic (Differential diagnosis section) . (
  • A mammography exam, called a mammogram, aids in the early detection and diagnosis of breast diseases in women. (
  • Trucut ultrasound guided biopsy (images shown) was performed (under local anesthesia) and at least 5 samples retrieved for histopathological evaluation which yielded Grade II invasive left breast ductal carcinoma . (
  • If the area of concern needs further evaluation, the next step may be an ultrasound and a breast biopsy. (
  • During a stereotactic breast biopsy, your breast will be firmly compressed between two plates. (
  • Breast X-rays (mammograms) are used to produce stereo images - images of the same area from different angles - to determine the exact location for the biopsy. (
  • The current study aimed to describe the profile of breast lesions in the records of women with positive biopsy or mastectomy findings from a reference laboratory in Yemen. (
  • Patients treated with breast-conserving surgery should not have a biopsy. (
  • A biopsy from a bone lesion revealed a metastasis of breast carcinoma. (
  • There were previously no clinical or histologic factors with significant (p ≤ 0.05) univariate or multivariate associations with the development of invasive carcinoma, although this cohort had experienced an unexpectedly high early development of invasive carcinoma, at median 5 years follow-up, that was predominantly associated with "lumpectomy alone" (referring to local excision alone, rather than the presence of a lump). (
  • Medullary carcinoma, mucinous carcinoma, and cribriform carcinoma are rare histologic types . (
  • D. ER-negative, HER2-positive papillary carcinoma - this is likely to be an invasive micropapillary carcinoma and have a poor prognosis (as opposed to ER+ invasive papillary carcinomas, which have a good prognosis). (
  • LCIS is a noninvasive condition in which abnormal cells are found in the lobules of the breast. (
  • Increases in vascular density, as detected with the CD34 antibody, correlates with recurrence and the development of invasive carcinoma. (
  • Purpose: The aim of this study was to determine the effect of timing of radiotherapy after conservative breast surgery on local recurrence in women with positive resection margins and young age, treated without systemic therapy. (
  • Patients with positive resection margins have higher local recurrence rates that become apparent when breast irradiation is delayed. (
  • Radiation therapy following breast-conserving surgery decreases mortality and recurrence. (
  • IMSEAR at SEARO: Lactating adenoma with infiltrating ductal carcinoma breast in a pregnant woman. (
  • In this type, the cancerous cells originate in the milk ducts and spread to other tissues in the breast. (
  • Infiltrative ductal carcinoma: It starts in the milk ducts of the breast. (
  • Furthermore, it is very important to differentiate between benign and malignant breast diseases in view of the clinical similarities between them [3]. (
  • The example below shows malignant neoplasm of breast detailed with laterality and specific anatomy. (
  • Lobular carcinoma starts in the lobules of the breast, where breast milk is produced. (
  • A skin-sparing mastectomy of the left breast with immediate reconstruction using ipsilateral deep inferior epigastric perforator (DIEP) flap was performed. (
  • 2 , 3 MRI allows identification of 15% (12-27%) additional occult malignancies in the ipsilateral breast and 4% (3-6%) in the contralateral breast. (
  • One and a half years left breast sub areola swelling -palpable fixed mass- post lactation with nipple retraction. (
  • Ductal carcinoma starts in the tubes (ducts) that carry milk from the breast to the nipple. (
  • Change in the size, shape, or feel of the breast or nipple. (
  • Make an appointment with your doctor if you notice a change in your breasts, such as a lump, an area of puckered or otherwise unusual skin, a thickened region under the skin, or nipple discharge. (
  • Changes in the skin of your breast or your nipple. (
  • The nipple and areola are shown on the outside of the breast. (
  • The ducts carry breast milk from the lobules, where it's made, to the nipple. (
  • The lobules are connected to the ducts, which carry breast milk to the nipple. (
  • This is similar as ductal carcinoma of nipple but can invade to surrounding tissues. (
  • An individual might experience pain in their breast area or nipple, which can at times be tied to that person's menstrual cycle. (
  • Patients with nipple-areola Paget's disease and underlying invasive breast carcinoma have very poor survival: a matched cohort study. (
  • They can also be used to detect and diagnose breast disease in women experiencing symptoms such as a lump, pain, skin dimpling or nipple discharge. (
  • Diagnostic mammography is used to evaluate a patient with abnormal clinical findings-such as a breast lump or nipple discharge-that have been found by the woman or her doctor. (
  • The results demonstrated that ANX2 and stromal tenascin C regulated invasion in addition to stemness and anoikis resistance, which are crucial for metastasis in the progression of pancreatic ductal adenocarcinoma. (
  • Pancreatic ductal adenocarcinoma (PDAC) represents an unmet clinical need due to the very poor prognosis and the lack of effective therapy. (
  • An invasive (infiltrating) CARCINOMA of the mammary ductal system ( MAMMARY GLANDS ) in the human BREAST . (
  • Moore SA, Notgrass HM, Vandergriff TW, Sahoo S. Mammary Paget's Disease of the Male Breast: A Rare Case With an Unusual Immunohistochemical Profile. (
  • Ablations needing ultrasound or MRI guidance for targeting ideally should be performed by physicians who are experienced at targeting breast lesions with image-guided needle biopsies. (
  • Mastectomy removes all or part of the breast and possibly nearby structures. (
  • Mastectomy - A surgeon removes all or a portion of an affected breast and lymph nodes. (
  • Understand options for having breast reconstruction or not after mastectomy. (
  • Two weeks later, I started five more rounds of chemo, followed by a mastectomy of my left breast. (
  • It may be performed with palpation guidance or with image guidance and is applicable in most patients with stage I or II invasive carcinomas. (
  • Which of the following invasive carcinomas has the best prognosis? (
  • is expressed by several gynecologic malignancies including common epithelial ovarian carcinomas and endometrial carcinomas. (
  • CSCs, as determined by the phenotypic expression of CD44+CD24?low, were detected in 63 instances of main invasive breast malignancy and their metastatic lymph node lesions from your same patient. (
  • C. ER-negative, HER2-positive ductal carcinoma - these are usually poorly differentiated, have high rates of proliferation and brain metastasis, and are associated with poor prognosis. (
  • The anatomopathological report indicated breast carcinoma metastasis and the pathologist recommended a further immunohistochemical investigation to determine the neoplastic site of origin. (
  • Intraductal carcinoma, comedo type. (
  • The remainder were lobular carcinoma (7 cases, 4.5%), medullary carcinoma (5 cases, 3.2%), intraductal carcinoma with Paget's disease (3 cases), mixed ductal-lobular carcinoma (2 cases) and tubular carcinoma (1 case). (
  • Paget's disease of the ectopic breast with an underlying intraductal carcinoma: report of a case. (
  • Paget's disease of the breast. (
  • Paget's disease of the male breast: case report and a point of view from actual literature. (
  • Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. (
  • Reduced E-cadherin expression correlates with disease progression in Paget's disease of the vulva but not Paget's disease of the breast. (
  • It can grow larger in your breast and spread to nearby lymph nodes or through your bloodstream to other organs. (
  • Cells may spread (metastasize) through your breast to your lymph nodes or to other parts of your body. (
  • METHODS: We analyzed QSOX1 mRNA expression in a cohort of 217 invasive ductal carcinomas of the breast. (
  • Mechanistic studies revealed that FOXD2AS1 upregulated the expression of the miR206 target gene ANXA2 in hepatocellular carcinoma by acting as a miR206 sponge. (
  • The Effect of Timing of Radiotherapy after Breast-conserving Surgery in Patients with Positive or Close Resection Margins, Young Age, and Node-negative Disease, with Long Term Follow-up" International Journal of Radiation Oncology, Biology, Physics Vol. 66 Iss. (
  • ARM I: Patients undergo standard whole breast irradiation (WBI) over 5-6 weeks. (
  • The treatment includes correction of breast asymmetries by using silicone breast implants in patients without cardiopulmonary symptoms, only with esthetic complaints. (
  • Six patients submitted only for breast prosthesis placement. (
  • In our sample, the placement of breast prostheses in the patients with pectus excavatum brought harmonic esthetic results, attenuating and/or masking the chest defect, with satisfactory esthetic results for the patients. (
  • Many patients are not satisfied with the cosmetic outcome after breast-conservation therapy. (
  • Case report: Patient aged 42 years, leukoderma, female, 8 years diagnosed with invasive breast ductal carcinoma. (
  • The data were the results of all fine-needle breast biopsies, excisional breast biopsies and biopsies of mastectomies carried out between January 1997 and December 2001 in a histopathology laboratory in Yemen. (
  • The signs and symptoms of Invasive Ductal Carcinoma of Breast (NOS) include lump in the breast, swelling or skin thickening around the region of the lump, and change in breast profile. (
  • At its earliest stages,invasive lobular carcinoma may cause no signs and symptoms. (
  • Infiltrative lobular carcinoma: It occurs at the breast lobules and may spread to the surrounding tissues. (
  • A further 20 blocks from The ISH results were given percentage vanced stages with a likely prevalence samples from normal breast tissues scores based on positive signals and of more aggressive tumour forms were labelled as a control group (i.e. number of cells that gave these signals. (
  • Many risk factors have been normal healthy breast tissues). (
  • TAG-72 is expressed by 80% of colorectal carcinomas but is rarely expressed in normal epithelium and benign diseases. (
  • This makes it imperative to have clinical breast examinations regularly. (
  • Women screened includes women receiving any NBCCEDP-funded screen (mammography, clinical breast exam, or Pap test). (